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Abstract 
 Cognitive symptoms are commonly reported by women diagnosed with breast 
cancer and have a negative impact on daily life. These cognitive changes are influenced 
by factors such as treatment (e.g., chemotherapy, hormone therapy), mood disruption, 
and even the cancer itself. In general, cognitive changes are subtle and affect multiple 
cognitive domains, although there is evidence that executive functioning may be 
particularly sensitive to the effects of breast cancer and its treatments. Most research in 
neuropsychology, including that with cancer populations, assesses mean performance 
level, which does not capture within-person variability. Intraindividual variability (IIV) is 
a different metric from measures of central tendency that examines fluctuations in task 
performance that are relatively transient and occur rapidly over short periods of time. IIV 
may provide novel information about cognitive functioning in cancer-related cognitive 
impairment. This dissertation first presents a systematic review of four specific cognitive 
subcomponents of executive function in breast cancer survivors: inhibition, set-shifting, 
working memory, and planning/decision making. Inhibition appears to be the 
subcomponent least affected by chemotherapy. Findings are mixed for set-shifting, 
working memory, and planning/decision making in part due to the heterogeneity in study 
methodologies. Next, two studies are reported which examine IIV in performance on a 
Stroop reaction time (RT) task as an indicator of cognitive functioning in women with 
breast cancer before and after chemotherapy compared to healthy controls assessed at 
similar time points. At baseline testing before surgery and neoadjuvant chemotherapy, 
breast cancer patients were more variable than healthy controls as task complexity 
increased (e.g., congruent vs. incongruent task conditions). Change scores from baseline 
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to 1-month postchemotherapy were similar between patients and controls on all Stroop 
measures. From baseline to 9 months postchemotherapy, however, patients did not 
improve as much as healthy controls did and IIV was more sensitive than mean RT in 
detecting group differences. Self-reported cognitive symptoms increased from baseline to 
9 months postchemotherapy, and change in symptoms associated with language and 
communication were positively correlated with change in variability. Taken together, the 
findings demonstrate that IIV is an important characteristic of cognitive performance in 
breast cancer patients. 
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Chapter 1: General Introduction 
Overview of Cognitive Performance in Women with Breast Cancer 
Breast cancer is the most common cancer diagnosis among Canadian women 
(Canadian Breast Cancer Foundation, 2015). In recent years, advances in breast cancer 
detection and treatment (e.g., surgical care, chemo-, radiation, and hormone therapies) 
have led to significantly improved survival rates (Park, Anderson, & Gail, 2015; Trudeau 
et al., 2005). Along with a focus on breast cancer survivorship comes an increased 
recognition that many women experience subtle impairments in cognitive performance. 
Although commonly referred to as “chemo brain” or “chemo fog,” it is now recognized 
that the neurotoxic effects of chemotherapy do not exclusively account for cognitive 
symptoms. There is growing evidence that cognitive dysfunction may also be related to 
the cancer itself, other cancer treatments (e.g., surgery, endocrine therapy), genetic 
factors (e.g., APOE ε4 allele), fatigue, and psychological distress (e.g., depression, 
anxiety; for reviews see Ahles, 2012; Seruga, Zhang, Bernstein, & Tannock, 2008). Thus, 
cancer-related cognitive impairment is a more accurate term to describe this 
phenomenon. The prevalence of cognitive decline ranges from 19 to 78% in women with 
breast cancer (Wefel & Schagen, 2012). Commonly affected cognitive domains include 
learning and memory, processing speed, and executive functioning (Wefel & Schagen, 
2012). 
Neuropsychological Studies of Cancer-Related Cognitive Impairment 
Early studies in this area had cross-sectional designs (Ahles et al., 2002; Brezden, 
Phillips, Abdolell, Bunston, & Tannock, 2000; Schagen et al., 2002; 1999; van Dam et 
al., 1998; Wieneke & Dienst, 1995). These studies compared breast cancer patients who 
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received chemotherapy to comparison groups (e.g., patients who did not receive 
chemotherapy, healthy controls, or normative data) and demonstrated variable findings 
with respect to the frequency and severity of impairment and the cognitive domains 
impaired after chemotherapy. Nevertheless, the collective evidence from these studies did 
suggest that a significant proportion of women experience cognitive deficits within two 
years after receiving chemotherapy. More recent cross-sectional studies also show late 
effects of chemotherapy in breast cancer survivors at 5 to 20 years posttreatment follow-
up (de Ruiter et al., 2011; Kesler, Kent, & O'Hara, 2011; Koppelmans et al., 2012; 
Nguyen et al., 2013; Scherwath et al., 2006).  
An important limitation of the cross-sectional studies is the failure to account for 
possible pretreatment differences between breast cancer patients and comparison groups. 
Thus, it is unclear whether the cognitive deficits observed in women with breast cancer 
result from chemotherapy exposure and/or are related to disease or patient factors. In fact, 
results from prospective studies indicate that approximately 20 to 30% of women 
diagnosed with breast cancer demonstrate impaired cognitive function prior to initiation 
of chemotherapy treatment (Bender et al., 2006; Hermelink et al., 2007; Jansen, Cooper, 
Dodd, & Miaskowski, 2011; Quesnel, Savard, & Ivers, 2009; Wefel, Saleeba, Buzdar, & 
Meyers, 2010). Pretreatment impairment appears to persist even after factors such as 
depression, anxiety and fatigue are accounted for (Bender et al., 2006; Hermelink et al., 
2007; Jansen et al., 2011). Other studies have shown that cancer-related posttraumatic 
stress is related to pretreatment impairment (Hermelink et al., 2015), and older age and 
lower cognitive reserve (Ahles et al., 2010) are risk factors for cognitive decline after 
chemotherapy. Together, findings suggest that the source of underlying pretreatment 
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cognitive impairment is likely multifaceted, and includes the effects of cancer itself, 
psychological distress, and other individual differences such as age or cognitive reserve. 
To date, prospective longitudinal studies of cognition in women with breast 
cancer have demonstrated inconsistent patterns of results. Although many studies show 
evidence of cognitive decline over the course of treatment (Ahles et al., 2010; Bender et 
al., 2006; Collins, MacKenzie, Stewart, Bielajew, & Verma, 2009; Hermelink et al., 
2007; 2008; Hurria et al., 2006; Jansen et al., 2011; Quesnel et al., 2009; Schagen, 
Muller, Boogerd, Mellenbergh, & van Dam, 2006; Shilling, Jenkins, Morris, Deutsch, & 
Bloomfield, 2005; Stewart et al., 2008; Vearncombe et al., 2009; Wefel, Lenzi, Theriault, 
Davis, & Meyers, 2004a), others report no significant decline (Debess, Riis, Engebjerg, 
& Ewertz, 2010; Jenkins et al., 2006; Mehlsen, Pedersen, Jensen, & Zachariae, 2009; 
Schagen et al., 2006; Tager et al., 2009). In general, the effects of impairment obtained 
from longitudinal studies are weaker than those reported in cross-sectional studies when 
pretreatment level of performance is accounted for, supporting the view that changes in 
cognition are subtle (Bender et al., 2006; Shilling et al., 2005; Stewart et al., 2008; Wefel, 
Lenzi, Theriault, Davis, & Meyers, 2004a).  
In terms of the time course of cognitive dysfunction after chemotherapy, some 
prospective studies report improved cognitive functioning among some patients at 1-year 
posttreatment, indicating that recovery does occur (Ahles et al., 2010; Hermelink et al., 
2007; Jansen et al., 2011; Jenkins et al., 2006; Shilling et al., 2005; Wefel, Lenzi, 
Theriault, Davis, & Meyers, 2004a). However, there is also evidence of persistent or 
delayed onset of cognitive decline after completion of chemotherapy treatment in other 
patients (Collins, MacKenzie, Tasca, Scherling, & Smith, 2014; Wefel et al., 2010).  
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The cognitive domains frequently affected include learning and memory, attention 
and concentration, executive function, and processing speed (Anderson-Hanley, 
Sherman, Riggs, Agocha, & Compas, 2003; Hodgson, Hutchinson, Wilson, & 
Nettelbeck, 2013; Wefel & Schagen, 2012), which are also the domains most often 
studied (Ono et al., 2015). However, deficits in motor function, visuospatial ability, and 
language are also reported (Falleti, Sanfilippo, Maruff, Weih, & Phillips, 2005; Jansen et 
al., 2011; Jim et al., 2012). Such patterns of impairment have led some researchers to 
suggest that cognitive dysfunction associated with chemotherapy is diffuse and 
nonspecific (Falleti et al., 2005) and others to claim a preferential dysfunction of frontal-
subcortical networks (Dietrich, Monje, Wefel, & Meyers, 2008; Wefel & Schagen, 2012).  
 The inconsistent findings are likely partly a result of substantial heterogeneity in 
study design and research methods. There are differences among neuropsychological 
studies in terms of: (a) patient sample characteristics, such as individual differences (e.g., 
age, education) and treatment regimens, which may include varying chemotherapy 
agents, dosages and schedules and the inclusion of other adjuvant treatments (e.g., 
hormone therapy); (b) neuropsychological tests used, which may have differing levels of 
sensitivity to detect subtle cognitive changes; (c) the comparator, such as healthy 
controls, disease-specific controls, or normative data; (d) criteria for defining and 
classifying cognitive impairment (e.g., 1 SD or 2 SDs below the mean) or reliable change 
(e.g., reliable change indices or standardized regression-based approaches); and (e) 
statistical analyses used, such as whether impairment is defined at the group or individual 
level and, in the case of longitudinal studies, whether and how the analyses control for 
practice effects associated with repeated testing.  
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Relationship Between Neuropsychological Performance and Self-Reported 
Cognitive Functioning in Women with Breast Cancer 
The prevalence of self-reported cognitive impairment ranges from 21 to 90% 
(Pullens, De Vries, & Roukema, 2010) in breast cancer survivors, with symptoms 
reported as many as 21 years following initial diagnosis (Koppelmans et al., 2012). 
Although the prevalence of cognitive impairment is similar between self-reported 
cognitive functioning and objective neuropsychological findings, there is a lack of 
correlation between the two assessment methods in women with breast cancer 
(Hermelink et al., 2010; Jansen et al., 2011; Jenkins et al., 2006; Shilling & Jenkins, 
2007). A similar dissociation between self-report and objective data are seen in other 
populations, including patients with HIV (Moore et al., 1997), traumatic brain injury 
(Schiehser et al., 2011), and normal older adults (Benito-Leon, Mitchell, Vega, & 
Bermejo-Pareja, 2010). Instead, it appears that self-reported cognitive symptoms have 
stronger associations with psychological factors such as anxiety (Hermelink et al., 2007; 
van Dam et al., 1998), depression (Hermelink et al., 2007; 2010; van Dam et al., 1998), 
negative affect (Hermelink et al., 2010), general psychological distress (Jenkins et al., 
2006; Shilling & Jenkins, 2007) and fatigue (Castellon et al., 2004; Servaes, Verhagen, & 
Bleijenberg, 2002), which suggest that self-reported cognitive symptoms and objective 
testing measure different phenomena (Pullens et al., 2010). It is also important to note 
that neuropsychological testing is typically conducted in a quiet, structured, and 
examiner-directed environment, which for most people capture their optimal level of 
functioning. Thus, patients may experience greater cognitive difficulties in more natural 
home, work, or community settings (Pullens et al., 2010). 
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Another potential explanation for the discrepant self-report and objective findings 
is the ability of patients to compensate for changes in cognitive function by recruiting 
greater neural resources during task performance. For instance, Ferguson, McDonald, 
Saykin, and Ahles (2007) reported a broader extent of neural activation on an n-back 
working memory task and higher levels of self-reported cognitive problems for a woman 
treated with chemotherapy compared to her healthy identical twin, although their levels 
of performance did not differ. Potential compensatory processes were also reported in a 
longitudinal fMRI study that used the n-back task with varying cognitive load on working 
memory (McDonald, Conroy, Ahles, West, & Saykin, 2012). This study found that 
although performance on the n-back task did not differ between chemotherapy and 
nonchemotherapy patient groups at any time points, there were alterations in activation 
patterns apparent at all three time points during low and high memory loads. Such 
findings suggest that mean performance level may not accurately reflect endogenous 
changes in the brain related to chemotherapy (e.g., neural activation patterns). 
Overview of Intraindividual Variability in Performance 
Within the breast cancer and cognition literature, the focus has been on 
differences or changes in mean performance level. When there is low performance 
variability, then mean performance levels may sufficiently characterize behaviour. 
However, as variability increases due to a general endogenous influence (e.g., reduced 
neurological integrity), performance as indexed by a single assessment can yield flawed 
estimates of group differences (Hultsch, Strauss, Hunter, & MacDonald, 2008). Thus, 
there is increased recognition that emphasis on mean level performance may be an 
oversimplification of behaviour that may lead to false inferences (Nesselroade, 2002).  
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Intraindividual variability (IIV) is a term used to describe within-person 
fluctuations in performance across RT trials within a given task (Hultsch et al., 2008; 
Nesselroade, 1991). This type of within-person variability differs from dispersion, which 
refers to variability across different tasks. Increased IIV in performance has been 
repeatedly associated with a number of neurological and neurodevelopmental conditions, 
including traumatic brain injury (Stuss, Murphy, Binns, & Alexander, 2003), dementia 
(Burton, Strauss, Hultsch, Moll, & Hunter, 2006; Murtha, Cismaru, Waechter, & 
Chertkow, 2002), mild cognitive impairment (Christensen et al., 2005; Dixon et al., 
2007), Parkinson’s disease  (Burton et al., 2006; de Frias, Dixon, & Camicioli, 2012), 
multiple sclerosis (Bodling, Denney, & Lynch, 2012), and attention deficit hyperactivity 
disorder (Williams, Strauss, Hultsch, Hunter, & Tannock, 2007). Furthermore, studies 
demonstrate a relationship between IIV and severity of neurological dysfunction, such 
that increased variability is associated with greater severity of neurological disturbance. 
In contrast, individuals with non-neurological diseases such as arthritis do not show 
increased IIV compared to healthy controls (Hultsch, MacDonald, Hunter, Levy-
Bencheton, & Strauss, 2000; Strauss, MacDonald, Hunter, Moll, & Hultsch, 2002). These 
findings suggest that IIV is informative in discriminating between neurologically intact 
and neurologically impaired individuals. 
Age-related Changes in Intraindividual Variability 
IIV is seen as a fundamental phenomenon of aging and has been largely studied 
within this context. The magnitude of IIV observed among healthy individuals has been 
found to fluctuate according to a U-shaped function across the lifespan from age 6 to 100 
years, with greater variability in performance observed in childhood/adolescence and 
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older adulthood relative to young adulthood and middle age (Williams, Hultsch, Strauss, 
Hunter, & Tannock, 2005). Similarly, a number of studies show that IIV increases as 
people age and appears to depend on task complexity (Bielak, Cherbuin, Bunce, & 
Anstey, 2014; Deary & Der, 2005). For example, an 8-year longitudinal study comparing 
IIV in young (20-24 years), middle (40-44 years), and older (60-64 years) adults found 
that IIV was stable for those in their 20s and 40s on a simple reaction time (RT) task 
(Bielak et al., 2014). However, IIV increased for those in their 60s over the course of the 
study. On complex RT tasks, both the middle and older adult groups showed greater 
variability than the young group over three assessment points with the older group 
demonstrating a larger difference. Thus, developmental change in IIV did not occur until 
older age for the simple RT tasks, but was observed in middle adulthood for the more 
complex task.  
Increased IIV has been associated with deleterious age-related outcomes. 
Virtually all published studies demonstrate positive associations between older age and 
IIV across both fluid (e.g., executive function, processing speed) and crystallized (e.g., 
semantic memory, vocabulary) cognitive abilities (Hultsch et al., 2008; Rabbitt, Osman, 
Moore, & Stollery, 2001). Bunce, MacDonald, and Hultsch (2004) showed that increased 
IIV in older adults is not due to slower motor processing, but rather is caused by 
increased attentional demands. In addition, experimental manipulations to elevate IIV 
levels in younger adults to that of older adults by degrading the visual stimuli were 
unsuccessful (MacDonald, Hultsch, & Bunce, 2006). These findings suggest that 
increased IIV in older adults is not due to sensory loss such as motor slowing or 
perceptual difficulties that may accompany normative aging but rather is attributable to 
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decreased attentional resources. 
Prospective longitudinal studies have also shown developmental changes in IIV 
and cognitive performance. For example, increases in IIV across a 6-year period were 
associated with corresponding 6-year declines in other cognitive domains of working and 
episodic memory (MacDonald, Hultsch, & Dixon, 2003). Similarly, significant inverse 
relationships were found between IIV and performance on cognitive tasks (Lövdén, Li, 
Shing, & Lindenberger, 2007), with stronger relationships between IIV and fluid 
measures that required greater cognitive load than more crystallized measures (Bielak, 
Hultsch, Strauss, MacDonald, & Hunter, 2010b).  
IIV provides information beyond that of mean-level performance (e.g., mean RT) 
despite the finding that these measures are often highly correlated (i.e., a wider response 
range tends to be associated with increases in both the mean and standard deviation 
because performance across trials is typically positively skewed). Although some studies 
find negligible predictive differences between the two measures in relation to cognitive 
outcomes (Christensen et al., 2005), other studies show that IIV contributes predictive 
information that is unique from mean-level performance (Li, Aggen, Nesselroade, & 
Baltes, 2001a; MacDonald, Nyberg, Sandblom, Fischer, & Bäckman, 2008b). In a 
particularly compelling investigation, increased IIV preceded and predicted subsequent 
decline in cognition, whereas mean-level performance did not (Lövdén et al., 2007). 
Altogether the findings indicate that, in addition to mean-level performance, IIV 
represents an important marker of cognitive integrity. 
Although the majority of research has focused on IIV as maladaptive in that it is 
associated with negative outcomes, variability may also serve as an indicator of resilience 
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and be associated with positive outcomes (Allaire & Marsiske, 2005). The issue of task 
characteristics is important because IIV in RT tasks that measure attention appear to 
follow a different pattern than IIV in other cognitive domains. For instance, increased IIV 
observed on learning tasks is proposed to be adaptive because the optimal method to 
perform a task is unknown and thus requires an individual to experiment with various 
strategies with room for growth and improvement (Allaire & Marsiske, 2005). In 
contrast, IIV in attentional tasks where response strategies are constrained is more likely 
to yield a maladaptive index of variability (Hultsch et al., 2002; Rabbitt et al., 2001). 
Phase of skill acquisition is another important consideration. Li, Huxhold, and Schmiedek 
(2004) proposed distinct functions of variability from initial learning to skill acquisition 
(e.g., reaching asymptotic performance level). Thus, IIV associated with initial 
acquisition of abilities may be considered adaptive, and IIV after asymptotic performance 
may reflect maladaptive functioning (MacDonald, Li, & Bäckman, 2009). 
Conceptualizations of Intraindividual Variability 
IIV has been hypothesized to represent momentary lapses of attention (Bunce, 
Warr, & Cochrane, 1993) or fluctuations in executive control processes (West, Murphy, 
Armilio, Craik, & Stuss, 2002). For example, whereas healthy older adults tend to exhibit 
significant correlations between IIV and cognitive performance regardless of task load, 
associations for younger adults are more likely to be observed only on more difficult 
tasks requiring frontally based executive processes (Hultsch, MacDonald, & Dixon, 
2002). These findings suggest that limited attentional resources are available for older 
adults relative to younger adults, with increased IIV as a behavioural manifestation of 
more frequent lapses in attention or fluctuations in executive control. Such observed 
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patterns converge with functional brain imaging studies that indicate involvement of 
frontal neural networks. In healthy older adults, white matter hyperintensities in the 
frontal lobe have been correlated with increased IIV (Bunce et al., 2007); in middle-aged 
adults, frontal white matter hyperintensities were correlated with increased IIV in 
women, whereas temporal white matter hyperintensities were correlated with IIV in men 
(Bunce et al., 2010). Increased IIV has also been associated with smaller corpus callosum 
volume in patients with mild cognitive impairment, particularly in the anterior region 
(Anstey et al., 2007). Patients with focal frontal lobe lesions (with the exception of 
ventral medial/orbitofrontal region) have also shown greater IIV than those with 
nonfrontal lesions and controls (Stuss et al., 2003). Similarly, people diagnosed with 
frontotemporal dementia are more variable on speeded tasks than those diagnosed with 
Alzheimer’s disease of similar disease severity (Murtha et al., 2002). 
The most widely used operationalization of IIV is the intraindividual standard 
deviation (ISD). ISD scores computed using raw scores have been criticized for 
containing both systematic within-person variability (e.g., practice effects, fatigue) and 
systematic between-group differences (e.g., group differences in overall mean 
performance are often correlated with differences in raw SD values). To address these 
issues, regression-based approaches are used to “purify” the data with respect to 
systematic trends in performance (Hultsch et al., 2008). Resulting residualized ISD scores 
have been found to increase as a function of age and cognitive status at a magnitude 
similar to raw ISDs (Dykiert, Der, Starr, & Deary, 2012). Another approach to 
understand the source of elevated variability involves restricting calculation of variability 
to the fast and slow tails of the RT distribution. This approach follows the hypothesis that 
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increases in IIV result from attentional or executive control lapses in the slow end of the 
RT distribution (Hultsch et al., 2002; Salthouse, 1993). This approach is an alternative to 
fitting the RT data to the ex-Gaussian distribution, which permits the analysis of the tau 
parameter representing the right tail of the RT distribution but is more computationally 
complex. 
Relevance of Intraindividual Variability for Women with Breast Cancer 
IIV appears to be an important characteristic of individual performance that 
represents a sensitive behavioural marker of neurobiological compromise (Li, 
Lindenberger, & Sikström, 2001b). The link between IIV and neurological functioning is 
potentially relevant for women treated for breast cancer because injury to the central 
nervous system resulting from neurotoxic effects of chemotherapy may underlie at least 
some cognitive symptoms. In the first study to investigate IIV in women diagnosed with 
breast cancer, Bernstein, Catton, and Tannock (2014) evaluated patients and healthy 
controls on a simple sustained Go-No Go attention task. Group differences were found 
under certain task conditions, such that patients with breast cancer were more variable 
than controls at short interstimulus intervals and less variable at longer intervals, which 
suggested greater difficulty on the shorter interval that involved increased cognitive load. 
IIV in that study was conceptualized using the coefficient of variation (CoV), which 
accounts for mean group differences but does not account for potential confounds of age 
or practice on RT. Nevertheless, the study findings provided a proof of concept that IIV 
is relevant for the study of cognitive dysfunction related to breast cancer and its 
treatments. 
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Study Aims and Overview 
The main purpose of this dissertation is to better understand executive functioning 
in women with breast cancer with an emphasis on exploring IIV in women before and 
after chemotherapy. First, a systematic review of published studies is presented (Chapter 
2). Studies were grouped according to four predefined subdivisions of executive 
functioning (Miyake, Emerson, & Friedman, 2000; Miyake & Friedman, 2012): (a) 
response inhibition, (b) set-shifting, (c) working memory, and (d) planning/decision 
making. The review chapter is followed by suggestions for future directions, including 
the use of methods beyond central measures of tendency--namely IIV--to evaluate 
performance of women treated for breast cancer.  
Chapter 3 reports an original study that examined pretreatment IIV in women 
diagnosed with breast cancer and healthy controls on a Stroop RT task. The Stroop task 
requires response inhibition and provides measures of increasing cognitive difficulty 
(e.g., congruent and incongruent task conditions). A secondary aim of the study was to 
examine whether demographic, clinical, and self-report variables are related to 
pretreatment IIV.  
 Chapter 4 presents a second study, which examined changes from baseline IIV 
among women treated with chemotherapy at 1-month and 9-month posttreatment 
compared to healthy controls assessed at similar intervals. Additional analyses examined 
change in self-reported cognition over the same assessment periods and correlations of 
self-reported cognitive symptoms with change in objective performance. The task 
paradigm includes task conditions that involve increasing cognitive load which allows for 
the examination of IIV associated with simple attention, as well as potential increases in 
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IIV associated with increases in cognitive demand (Hultsch et al., 2000). IIV results are 
also discussed in relation to mean-level performance (i.e., mean RT) to determine 
whether IIV provides unique information regarding cognitive performance in women 
treated for breast cancer.  
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Chapter 2: Do Women Treated For Breast Cancer Have Impaired 
Executive Functioning? A Systematic Review 
Publication Status 
The following chapter is based on a manuscript in preparation for publication: 
Yao, C., Bernstein, L. J., & Rich, J. B. Executive functioning impairment in women 
treated for breast cancer with chemotherapy: A systematic review.  
Abstract 
Women treated for breast cancer may experience cognitive difficulties following 
chemotherapy. Impaired performance on tasks examining executive functioning is 
commonly observed, yet it isn’t clear whether some subcomponents of executive 
functioning are more vulnerable to impairment than others. A comprehensive systematic 
review of articles that reported quantitative information on executive functioning among 
breast cancer survivors who had been treated with chemotherapy was performed. Studies 
were identified using three electronic databases (MEDLINE, PsycINFO, and Web of 
Science) and a manual search of relevant reference lists. The methodological quality of 
included studies was assessed using a checklist of predefined criteria. Of 1227 identified 
articles, a total of 36 were included for review. Study findings were categorized into four 
subcomponents of executive functioning: inhibition, set-shifting, working memory, and 
planning/decision-making. Inhibition appears relatively spared from the effects of 
chemotherapy, whereas findings were inconsistent for set-shifting, working memory, and 
planning/decision making. Methodological heterogeneity contributed to the mixed 
findings. Examining subcomponents of executive functioning is recommended to better 
characterize the nature of executive dysfunction in women treated with chemotherapy. 
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Future studies should include executive functioning tasks of varying complexity, use of 
individual and composite measures, and alternative indices to capture performance, such 
as within-person variability. 
Introduction 
Many women with breast cancer experience subtle impairments in cognitive 
performance associated with chemotherapy. Although many prospective studies 
demonstrate that cognitive dysfunction improves within one year after the completion of 
chemotherapy (Collins et al., 2009; Jansen et al., 2011; Reid-Arndt, Hsieh, & Perry, 
2010), some cognitive deficits persist (Collins et al., 2014; Wefel et al., 2010). Cross-
sectional studies have documented long-term cognitive deficits up to 21 years from initial 
diagnosis (de Ruiter et al., 2011; Koppelmans et al., 2012; Nguyen et al., 2013), and these 
deficits can have an adverse impact on quality of life (Reid-Arndt et al., 2010). Executive 
functioning is commonly investigated in these studies. Despite reports of deficits on tasks 
of executive functioning following chemotherapy among women with breast cancer 
(Chen et al., 2013; Hermelink et al., 2007; Jim et al., 2009; Nguyen et al., 2013), some 
studies demonstrate normal performance (Ahles et al., 2010; Castellon et al., 2004; 
Jenkins et al., 2006; Mehlsen et al., 2009; Vearncombe et al., 2009). The inconsistent 
findings may be related to differences in study characteristics, such as the breast cancer 
population under study (age, stage of tumor, menopausal status), type of comparison 
cohort (healthy controls, other cancers, untreated patients, normative data), time since 
diagnosis or treatment, type of treatment (e.g., chemotherapy alone vs. in combination 
with hormonal or radiation, chemotherapy dose), and study design (cross-sectional or 
longitudinal; Ahles, 2012; Collins, MacKenzie, & Kyeremanteng, 2013a; Edelstein & 
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Bernstein, 2014). Another reason for the inconsistent findings may be related to the 
complexity of the executive functioning construct itself. 
Executive functioning includes a set of cognitive processes involved in goal-
directed behavior and adaptation to novel situations and is often linked to the prefrontal 
cortex. The extent to which executive functioning represents a unitary concept reflecting 
activation of one underlying neural network or separate, dissociable concepts is an area of 
considerable debate (Duncan & Owen, 2000; Jurado & Rosselli, 2007; Stuss, 2011). 
Another confounding factor is the issue of task impurity, which arises because many tests 
of executive functioning also require nonexecutive processes for task completion 
(Miyake & Friedman, 2012). For example, performance on the Trail Making Test, Part B, 
a measure of set-shifting, additionally draws upon psychomotor speed, visual scanning, 
and sequencing. Although executive functioning has been difficult to define and measure 
(Jurado & Rosselli, 2007), an accepted schema that reflects the cognitive and biological 
underpinnings of executive functioning is the unity and diversity framework (Miyake et 
al., 2000; Miyake & Friedman, 2012). This framework suggests that different executive 
functions tap a common underlying ability and are generally correlated (i.e., unity) but 
are also dissociable (i.e., diversity). Four separable subcomponents that may be useful for 
classifying executive functioning tasks include: (a) inhibition: deliberate overriding of a 
dominant or prepotent response; (b) set-shifting: switching between tasks or mental sets; 
(c) working memory: monitoring incoming information and rapid addition or deletion of 
working memory contents; and (d) planning and decision making (Friedman et al., 2008; 
Miyake & Friedman, 2012). 
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Within the breast cancer literature, various neuropsychological and experimental 
tasks have been used to assess executive functioning across studies. Some studies rely on 
a single measure, whereas others include multiple measures or use a composite measure 
to operationalize executive functioning. Previous meta-analyses and reviews have been 
published examining the magnitude and pattern of executive impairment in breast cancer 
patients treated with chemotherapy; however, these studies typically average across all 
executive functioning measures to yield an aggregate score (Anderson-Hanley et al., 
2003; Falleti et al., 2005; Ono et al., 2015). In the present review, we compare 
performance across different tasks of executive abilities to determine whether any 
subcomponents of executive functioning are more sensitive than others to dysfunction 
following chemotherapy. 
Methods 
Search Strategy 
 A systematic literature search was conducted using the following electronic 
databases: MEDLINE (1966–2016), PsycINFO (1872– 2016), and Web of Science 
(1945–2016). The key search terms used were “breast cancer” AND cogni* AND 
(“executive function*” OR frontal OR prefrontal OR neuro* OR assessment). In addition, 
reference lists from included papers were manually searched to help ensure that no 
relevant studies were missed through the electronic databases. 
Study Selection 
 The review was limited to studies using women with breast cancer and published 
in English. Studies were included if they reported on at least one standardized 
neuropsychological test or objective experimental measure of executive functioning. 
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Initial screening for inclusion was based on titles of all identified papers, followed by 
abstract and full-text screening. When multiple studies shared an overlapping patient 
sample, only the highest quality study (as detailed below) was included (Khan, Kunz, 
Kleijnen, & Antes, 2003; Pullens et al., 2010). 
Methodological Quality Assessment 
 Two raters (CY and a research assistant) independently assessed the quality of 
each study using a standardized set of 17 predefined criteria (Table 1) adapted from 
Pullens and colleagues (2010). Studies earned 0 or 1 point for each criterion in the 
checklist. A score of 0 was assigned if insufficient information was provided for rating a 
given criterion. Discrepancies between raters were discussed among all authors to reach 
consensus. Studies scoring 70% or more of the maximum score (≥ 12 points) were 
categorized as high quality. Studies scoring between 50% and 70% (9 -11 points) were 
categorized as moderate quality, and studies with ≤ 8 points were considered low quality. 
Level of agreement between raters was analyzed using the intraclass correlation 
coefficient (ICC; Bartko, 1966; 1966). 
Results 
Search Strategy and Quality Assessment 
 The search strategy identified 1227 articles. Figure 1 provides a flowchart of the 
article selection process. After removing duplicates, excluding articles based on title, 
abstract, and full-text screening, and adding articles identified manually, a total of 36 
studies were eligible for inclusion in the final review. The included studies were 
published between 1995 and 2016, with half of the studies published in 2010 or later. 
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Table 1. Checklist to Assess Methodological Quality of Included Articles (Modified 
from Pullens et al., 2010) 
 
  
Criteria 
 
Study Population 
A. Patient signed an informed consent form before study participation 
B. A description is present of at least two sociodemographic data (e.g., age, race, 
employment status, educational status, etc).  
C. Medical data are described (e.g., tumor stage at diagnosis, treatment, etc.) 
D. Inclusion and/or exclusion criteria are formulated 
E. Participation and response rates for patient groups have to be more than 75% 
F. Information is presented about patient/disease characteristics of nonresponders or 
reasons for not participating 
 
Study Design 
G. Sample size is at least 50 patients (arbitrarily chosen) 
H. The process of data collection is described (e.g., neuropsychological assessments, 
self-report measurements, interview) 
I. More than one neuropsychological measure to assess executive functioning is 
described 
J. A baseline measurement is obtained before treatment 
K. There are multiple assessment points 
L. Mean or median and range or standard deviation of time before/since 
diagnosis/treatment or test interval between measurement occasions is given 
M. Data collection is prospectively gathered 
N. Drop out rate is less than 20% 
O. The study controlled for at least two of the following factors in the results for 
executive functioning: depressive symptoms, fatigue, anxiety, stress, menopausal 
status, influence of hormonal therapy, educational level, or age 
 
Results 
P. The results for executive functioning are compared between two or more groups 
(e.g., healthy population, different treatment groups, comparison with time, etc.) 
Q. An appropriate statistical test was used 
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Figure 1. Study Search Flowchart  
 
PsycINFO 
(206) 
Medline 
(381) 
Web of Science 
(640) 
Computerized search total 
(1227) 
Titles screened total 
(778) 
Duplicates removed (449) 
Studies excluded based on title (598) 
Abstracts screened total 
(180) 
Full-text screened total 
(112) 
Studies excluded based on abstract (68) 
 
- Executive functioning not a primary outcome (22) 
- Reviews or editorials (20) 
- Methodological or intervention studies (8) 
- Case report (2) 
- No Chemotherapy (9) 
- Only pretreatment data reported (7) 
Included studies from 
computerized search (31) 
Studies excluded based on full-text (81) 
 
- Sample overlap (30) 
- Not exclusively BC patients (8) 
- Executive functioning not a primary outcome (37) 
- Methodological or intervention studies (6) 
 
Total studies included (36) 
Added after hand search (5) 
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Inter-rater agreement of methodological quality assessment was high (ICC = .80). On a 
17-point scale, the average score was 11.95 (SD = 2.36, range = 8 to 16). 
Executive Functioning Subdivisions  
The cognitive tasks that were used to assess executive functioning are described 
in Table 2. The results are presented according to Miyake and Friedman’s (2012) unity 
and diversity framework of executive functioning. The outcome data were assigned to a 
subcomponent by using generally accepted descriptions (Lezak, Howieson, Bigler, & 
Tranel, 2012) or author report. Characteristics of the included studies are provided in 
Table 3. The findings from each study are summarized in Table 4. 
Inhibition 
Inhibition was assessed in 13 studies using the Stroop task (time to completion or 
age/education-corrected standardized scores). Only one high quality cross-sectional study 
found that patients treated with chemotherapy were slower compared to those who did 
not undergo chemotherapy or healthy controls at 1-month follow-up (Chen et al., 2013). 
The other 12 studies (five cross-sectional, seven longitudinal) did not show impaired 
performance in patients at short-term (up to 1 year after treatment; Debess et al., 2010; 
Deprez et al., 2011; Hurria et al., 2006; 2014; Jansen et al., 2011; Jenkins et al., 2006; 
Mehlsen et al., 2009; Reid-Arndt et al., 2010; Vearncombe et al., 2009) or long-term 
follow-up (up to 21 years after treatment; Castellon et al., 2004; Koppelmans et al., 2012; 
Schagen et al., 1999; van Dam et al., 1998). One low-quality cross-sectional study used a 
Flanker test (de Ruiter et al., 2011), and found patients treated with chemotherapy made 
more errors than patients who did not receive chemotherapy at 9 years posttreatment. 
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Together, the studies published to date suggest that inhibition is not impaired in patients 
after chemotherapy.  
Set-Shifting 
Twenty-five studies have assessed set-shifting. Women treated with 
chemotherapy were impaired on the Trail Making Test, Part B (TMT-B) in four 
moderate- to high-quality studies (2 cross-sectional and 2 longitudinal; Chen et al., 2013; 
2013; Mar Fan et al., 2005; Schagen et al., 1999; Wefel et al., 2010), whereas they 
performed similarly to control groups in 17 other investigations of similar 
methodological quality (Bender et al., 2006; Biglia et al., 2011; Castellon, Silverman, & 
Ganz, 2005; Donovan et al., 2005; Hermelink et al., 2007; Hurria et al., 2006; Jim et al., 
2009; Mehlsen et al., 2009; Nguyen et al., 2013; Quesnel et al., 2009; Reid-Arndt et al., 
2010; Ruzich, Ryan, Owen, Delahunty, & Stuart-Harris, 2007; Scherwath et al., 2006; 
Tager et al., 2009; van Dam et al., 1998; Wefel, Lenzi, Theriault, Davis, & Meyers, 
2004a; Wefel, Lenzi, Theriault, Buzdar, Cruickshank, & Meyers, 2004b; Wieneke & 
Dienst, 1995). Group differences were found 1 to 6 months and 1 to 2 years after 
treatment, but not when assessments were undertaken up to 5 to 10 years after treatment 
(Castellon et al., 2005; Nguyen et al., 2013; Scherwath et al., 2006). 
Three studies assessed set-shifting using the Wisconsin Card Sorting Test 
(WCST). Two cross-sectional studies of moderate quality showed impaired performance 
in breast cancer survivors 5 to 10 years after chemotherapy (e.g., fewer categories 
completed, greater number of errors, increased time to completion; Kesler et al., 2011; 
Nguyen et al., 2013), although one of them found that patients were impaired relative to 
healthy controls but not to patients who did not receive chemotherapy (Nguyen et al., 
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2013). In one 6-month longitudinal study of moderate quality, patients showed 
improvement over assessments (Ruzich et al., 2007). However, no comparison groups 
were included in the study, so practice effects common to this test were not accounted for 
across four measurement occasions (Basso, Bornstein, & Lang, 1999; Ferland, Ramsay, 
Engeland, & O'Hara, 1998).  
Among the seven studies using other variants of set-shifting tasks, two high-
quality longitudinal studies found decline within 1 month after chemotherapy on a trail-
making type test (Debess et al., 2010) and on a test of verbal fluency involving category 
switching (Hermelink et al., 2007). In contrast, five studies of high to moderate quality 
did not find impairments from immediately postchemotherapy up to 10 years later using 
D-KEFS Sorting Test (Ahles et al., 2010; Vearncombe et al., 2009), Booklet Category 
Test (Wefel, Lenzi, Theriault, Davis, & Meyers, 2004a; Wieneke & Dienst, 1995) and a 
computerized test of concept shifting (Nguyen et al., 2013). 
Together, the studies using set-shifting tasks do not corroborate consistent 
chemotherapy-related impairments. There were methodological differences between 
studies with respect to the particular tests used to assess set-shifting, outcome measures 
(e.g., total correct vs. standardized score), and comparison group (e.g., healthy controls 
vs. normative data), which make direct comparison challenging and contribute to the 
inconsistent findings.  
Working Memory 
Twenty-four studies evaluated working memory using individual 
neuropsychological tests and working memory composites. Using Digit Span Backward 
(DSB), four cross-sectional studies of 13 studies that used this task, ranging from low to 
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high quality, observed reduced span and fewer total trials completed in women treated 
with chemotherapy compared to no chemotherapy and healthy control groups up to 2-
year follow-up (Chen et al., 2013; Deprez et al., 2012; Jung & Cimprich, 2014; Schagen 
et al., 1999). The remaining studies (3 cross-sectional; 6 longitudinal) ranging from 
moderate to high quality found similar performance in patients and control groups up to 2 
years posttreatment (Bender et al., 2006; Deprez et al., 2011; Hermelink et al., 2007; 
Mehlsen et al., 2009; Quesnel et al., 2009; Scherwath et al., 2006; Tager et al., 2009; van 
Dam et al., 1998; Vearncombe et al., 2009). 
Working memory was also assessed using Letter-Number Sequencing (LNS). 
LNS performance was impaired in women treated with chemotherapy at 4-month follow-
up in a moderate-quality cross-sectional study (Deprez et al., 2012). In another moderate-
quality cross-sectional study, chemotherapy-treated patients performed worse than 
healthy controls 10 years posttreatment, although they did not differ from 
nonchemotherapy-treated patients (Nguyen et al., 2013). In three other longitudinal 
studies of moderate to high quality, performance was unimpaired at short-term follow-up 
(Mehlsen et al., 2009; Ruzich et al., 2007; Tager et al., 2009), although the effects of task 
repetition were not consistently controlled due to lack of control groups in one of these 
studies (Ruzich et al., 2007). 
On the Arithmetic test, women treated with chemotherapy did not differ from 
comparison groups when assessed immediately postchemotherapy up to 10 years later in 
one cross-sectional (Nguyen et al., 2013) and three longitudinal studies (Ruzich et al., 
2007; Tager et al., 2009; Wefel, Lenzi, Theriault, Davis, & Meyers, 2004a). Two of these 
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studies did not include control groups (Ruzich et al., 2007; Wefel, Lenzi, Theriault, 
Davis, & Meyers, 2004a). 
One moderate-quality cross-sectional study that used the Paced Auditory Serial 
Addition Test (PASAT) found impaired performance in patients 6 months 
postchemotherapy treatment relative to normative data (Wieneke & Dienst, 1995). Two 
other studies of high or moderate quality found no group differences on PASAT 
performance in relation to comparison groups up to 5 years after diagnosis (Ahles et al., 
2010; Castellon et al., 2004). 
Other variants of the working memory tasks (e.g., n-back) used in three moderate- 
to high-quality longitudinal studies did not find group differences in change at 1-month 
(Askren et al., 2014; McDonald et al., 2012) and 1-year postchemotherapy (Dumas et al., 
2013).  
Finally, two high-quality longitudinal studies generated working memory 
composite scores based on five to seven tests (e.g., Digit Span, LNS, PASAT, Arithmetic, 
Spatial Span, Consonant Trigrams, Controlled Oral Word Association test, CNS-VS 
Flexibility Index, CNS-VS Working Memory Index). Composite scores were calculated 
by averaging standardized scores determined by principal components analysis (Collins 
et al., 2014) or using standard regression-based change scores based on the performance 
of healthy controls (Collins et al., 2009). Both of these studies found significant working 
memory impairments in chemotherapy-treated patients assessed immediately 
posttreatment. Furthermore, over the course of treatment, working memory worsened 
with each additional chemotherapy cycle given (Collins et al., 2014). 
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As with the other subcomponents, there is methodological heterogeneity which 
likely contributes to inconsistent findings in this subcomponent of executive functioning.  
Planning/Decision Making 
 Three studies investigated planning/decision making. Using the Iowa Gambling 
Task (IGT) and Game of Dice Task (GDT), one high-quality cross-sectional study (Chen 
et al., 2013) showed that patients treated with chemotherapy showed a selective deficit 
when information on probabilities was ambiguous (IGT) at 6-month follow-up. Assessing 
planning using the Tower of London (ToL), a low-quality cross-sectional study found 
breast cancer patients treated with chemotherapy made more errors on the ToL task at 10-
year follow-up than did a group of patients not exposed to chemotherapy (de Ruiter et al., 
2011). In contrast, a moderate-quality longitudinal study reported that ToL performance 
did not change when tested during and 6 months after chemotherapy (Ruzich et al., 
2007); however, practice effects were not accounted for. There is inconsistent evidence of 
impaired decision-making ability and planning/problem. Impairment was observed in 
cross-sectional but not longitudinal studies.  
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Table 2. Task Descriptions of Executive Functioning Measures  
Executive Functioning 
Subdivision 
Task Task Requirements 
Inhibition: ability to 
suppress a response 
based on a set of 
predefined rules.  
Stroop task (Golden & 
Freshwater, 2002; 
Gualtieri & Johnson, 2006; 
Hammes, 1978; Houx, 
Jolles, & Vreeling, 1993; 
Mitrushina, Boone, & 
D'Elia, 1999; Stroop, 
1935)  
Say the ink color of written words while 
inhibiting the automatic response, which 
is to read the word (e.g., responding 
“blue” when viewing the word red 
written in blue ink).  
 
Flanker task (Eriksen & 
Schultz, 1979) 
 
Respond to a target letter and refrain 
from responding to the target letter when 
flanked by distracting letters. 
 
Set-Shifting: ability to 
switch between tasks, 
operations or mental 
sets in response to 
changing goals or 
environmental 
demands.  
 
Trail Making Test – Part B 
(Reitan, 1958); Concept 
Shifting Test (Vink & 
Jolles, 1985) 
 
Order a series of numbers and letters in 
alternating sequence (e.g., 1-A-2-B-3-C) 
as quickly and accurately as possible. 
 
Color Trails Test – Trial 2 
(D'Elia, Satz, Uchiyama, 
& White, 1996) 
 
Connect colored number targets in 
numerical order in an alternating color as 
quickly as possible 
 
Wisconsin Card Sorting 
Test (Heaton, 2004; 
Heaton, Chelune, Talley, 
Kay, & Curtiss, 1993) 
 
Sort a deck of cards in relation to four 
key cards while alternating sorting 
strategies (e.g., color, shape, number) in 
response to feedback from the examiner 
or computer 
 
D-KEFS Sorting Test 
(Delis, Kaplan, & Kramer, 
2001) 
 
Sort six cards into two groups, according 
to as many rules as possible, and then are 
given the opportunity to identify the rules 
from cards sorted by the examiner. 
 
Booklet Category Test 
(DeFilippis, McCampbell, 
& Rogers, 1979) 
 
Determine the underlying organizational 
principle of sets of stimuli using feedback 
from the examiner. 
 
Intradimensional/Extra-
dimensional Shift Task 
(Sahakian & Owen, 1992) 
 
Shift attention between intra- and 
extradimensional stages (e.g., shapes 
overlaid with lines) based on feedback 
  
Regensburg Word Fluency 
 
Alternate between saying words from two 
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Note. D-KEFS = Delis-Kaplan Executive Function System; WAIS=Wechsler Adult Intelligence Scale. 
  
with category change 
(Aschenbrenner, Tucha, & 
Lange, 2000) 
different semantic categories. 
 
Working Memory: 
involves the ability to 
hold and manipulate 
information in mind for 
a short period of time. 
 
Digit Span Backward, 
WAIS (Wechsler, 1955; 
1981; 1997) 
 
Verbally repeat a string of numbers in 
reverse order. 
 
Letter Number 
Sequencing, WAIS 
(Wechsler, 1997)!
 
Reorder random alphanumeric sequences 
presented orally!
 
Arithmetic, WAIS 
(Wechsler, 1981; 1997)!
 
Mentally solve mathematical word 
problems as quickly as possible.!
!  
Paced Auditory Serial 
Addition Test (Fischer, 
Jak, Kniker, Rudick, & 
Cutter, 2001; Gronwell, 
1977; Rao, Leo, 
Bernardin, & Unverzagt, 
1991)!
 
Serial addition of pairs of randomly 
presented numbers from 1 to 9, such that 
each number is added to the one that 
immediately preceded it (i.e., the 
numbers 4, 3, 5, 9, 2 yield responses of 7, 
8, 14, 11).!
!  
n-back task (McAllister et 
al., 1999)!
 
Participants are shown a series of letters 
or shapes one at a time and determine 
whether the current item was presented 0-
, 1-, 2- or 3-back in the sequence.!
 
Planning/Decision 
Making: involves 
mental processes such 
as planning, rule 
acquisition, initiating 
appropriate responses, 
and selecting relevant 
information. 
 
Iowa Gambling Task 
(Bechara, Damasio, 
Damasio, & Anderson, 
1994)  
 
Choose cards from four decks to 
maximize gains using feedback from 
previous choices to learn the rules for 
gains/losses of each deck. 
 
Game of Dice Task (Brand 
et al., 2002) 
 
 
Maximize gains by tossing a die with 
explicit rules for gains/losses and stable 
probabilities (two risky and two non-
risky options) 
 
Tower of London 
(Shallice, 1982; van den 
Heuvel et al., 2003)  
 
Determine the minimum number of steps 
required to reach a target configuration of 
colored beads placed on vertical rods. 
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Table 3. Study Characteristics of Included Studies 
Author (Year) 
Participants       
Measurement Interval 
ChT patients   No ChT patients  Healthy Controls 
Age M (SD) n  Age M (SD) n  Age M (SD) n 
Cross-sectional Studies 
High Quality          
   Chen (2013) 43.7 (7.7)  63  44.3 (8.9) 62  42.0 (9.7) 61 1 month post ChT 
   Donovan (2005) 52.3 (8.1) 60  - -  57.7 (9.1) 83 6 months post ChT 
   Koppelmans (2012) 64.1 (6.4) 196  - -  57.9 (5.4) 1,509 21 years after diagnosis 
Moderate Quality          
   Castellon (2004) 46.8 (6.3) 36  48.3 (4.0) 17  49.2 (6.0) 19 2-5 years after diagnosis 
   Deprez (2011) 45.4 (4.5)  14  42.9 (6.15) 10  45.1 (4.0) 15 4 months post ChT 
   Jim (2009) 50 (9)  97  58 (9) 90  Matched to 
ChT: 53 (8)  
Matched to no 
ChT: 59 (9) 
97 
 
90 
6 months post ChT  
   Kesler (2011) 56.2 (7.8)  25  58.1 (6.5) 19  55.6 (9.4) 18 5 years since ChT  
   Nguyen (2013) 72.0 (4.9)  27  76.7 (5.4) 30  72.6 (5.5) 30 10+ years since ChT  
   Schagen (1999) 47.1 (6.5) 39  46.1 (5.2) 34  - - 2 years post ChT  
   Scherwath (2006) Std ChT: 51.8 (8.6);  
Hi ChT: 53.3 (7.1) 
23 
24 
 54.6 (8.0) 29  - - 5 years post ChT  
   Van Dam (1998) Std ChT: 48.1 (6.8);  
Hi ChT: 45.5 (6.2) 
36 
34 
 46.1 (5.2) 34  - - 
 
2 years post ChT  
   Wieneke (1995) 42.0 (6.7) 28  - -  - - 6 months post ChT 
Low Quality          
   De Ruiter (2012) 56.5 (5.1) 17  58.2 (5.8) 15  - - 9.5 years post ChT 
   Jung (2014) 46 (8) 32  - -  48 (8) 32 2 months post ChT 
 
Longitudinal Studies 
High Quality          
   Ahles (2010) 51.7 (7.1)  60  56.6 (8.3) 72  52.9 (10.0) 45 Baseline, 1 month, 6 month, 18 
months post ChT  
   Askren (2014) 50 (10) 28  53 (9) 37  50 (9) 32 Baseline, 1 month post ChT 
   Bender (2006) ChT: 40.1 (6.5) 
ChT/HT: 44.1 (3.5) 
19 
15 
 44.5 (4.2) 12  - - 
 
Baseline, immediately post ChT, 
1-year later 
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Author (Year) 
Participants       
Measurement Interval 
ChT patients   No ChT patients  Healthy Controls 
Age M (SD) n  Age M (SD) n  Age M (SD) n 
   Collins (2014) 51.8 (7.8) 56  - - 
 
 51.3 (7.7) 56 Baseline, after each ChT cycle, 1-
year post ChT 
   Debess (2010) 47.2 75  49.7 19  48.1 208 Baseline, 1-month post ChT 
   Deprez (2012) 43.7 (6.1) 34  43.1 (5.7) 16  43.8 (4.9) 19 Baseline, 3-4 months post ChT 
   Hermelink (2007) 48.6 (9.7) 101  - -  - - Baseline; immediately post ChT 
   Jansen (2011) 
  
ChT: 50.9 (2.2) 
ChT/HT: 50.7 (1.6) 
22 
49 
 - -  - - Baseline, immediately post ChT, 
6 months post ChT  
   Jenkins (2006) 51.5 (9.6) 85  58.9 (7.3) 43  51.9 (8.9) 49 Baseline, immediately post ChT, 
1-year post ChT 
   Quesnel (2009) 50.3 (7.2) 41  57.7 (4.9) 40  Matched to 
ChT: 47.9 (7.4)  
Matched to no 
ChT: 55.0 (7.1) 
22 
 
23 
Baseline, immediately post ChT, 
3 month follow-up 
   Tager (2010) 60.3 (5.6) 30  61.1 (6.2) 31    Baseline, immediately post ChT, 
6-months follow-up 
   Vearncombe (2009) 49.4 (7.9) 
 
136  54.0 (8.2) 
 
21  - - Baseline, immediately post ChT  
   Wefel (2010) 48.8 (8.1) 42  - -  - - Baseline, During ChT (acute), 
immediately after ChT (acute), 1-
year post ChT (late) 
   Wefel (2004) 45.4 (6.7) 18  - -  - - Baseline, immediately post ChT, 
1-year post ChT 
Moderate Quality          
   Biglia (2012) 51.0 (7.8) 40  - -  - - Baseline, immediately post-ChT  
   Dumas (2013) 57.10 (8.6) 9  - -  - - Baseline, 1-month post ChT, 1-
year follow-up 
   Hurria (2006) 71 (5) 28  - -  - - Baseline, 6-months post ChT  
   Mar Fan (2005) Median age: 48 104  - -  Median age: 47 102 
 
Immediately post ChT, 1-year, 2-
year follow-up 
   McDonald (2012) 52.9 (8.6) 16  52.7 (7.2) 12  50.5 (6.0) 15 Baseline, 1-month post-ChT, 1-
year later 
   Mehlsen (2009) 48.6 (8.0) 36  Cardiac group: 
50.4 (9.1) 
14  39.3 (11.7) 17 
 
Baseline, 1-month post ChT 
   Reid-Arndt (2010) 53.4 (9.6) 39  - -  - - 1-month post-ChT, 6-month and 
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Author (Year) 
Participants       
Measurement Interval 
ChT patients   No ChT patients  Healthy Controls 
Age M (SD) n  Age M (SD) n  Age M (SD) n 
1-year follow-up 
   Ruzich (2007) Median age: 53 35  - -  - - Baseline, mid ChT, post ChT, 6-
month post ChT 
Note. BC=Breast Cancer; ChT= chemotherapy; COWA= Controlled Oral Word Association; D-KEFS=Delis-Kaplan Executive Function System; 
DSB= Digit Span Backward; EF=Executive Functioning; LNS= Letter-Number Sequencing; HT=Hormone Therapy; PASAT= Paced Auditory Serial 
Addition Test; RT= Radiotherapy; RWT= Regensburger Word Fluency Test; sig.=significant; SX= Surgery; TMT-B= Trail Making Test – Part B; 
ToL=Tower of London; TX= treatment; WCST= Wisconsin Card Sorting Test.
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Table 4. Results of Included Studies 
Author (Year) 
Study 
Design Measure Resultsa 
A. INHIBITION 
High Quality    
Chen (2013) C Stroop ChT < Non-ChT, HC  
Koppelmans (2012) C Stroop ns 
Debess (2010) L Stroop ns 
Jansen (2011) L Stroop ns 
Jenkins (2006) L Stroop ns 
Vearncombe (2009) L Stroop ns 
Moderate Quality    
Castellon (2004) C Stroop ns 
Deprez (2011) C Stroop ns 
Schagen (1999) C Stroop ns 
Van Dam (1998) C Stroop ns 
Hurria (2006) L Stroop ns 
Mehlsen (2009) L Stroop ns 
Reid-Arndt (2010) L Stroop ns 
Low Quality    
De Ruiter (2012) C Flanker test ChT < Non-ChT  
B. SET-SHIFTING 
High Quality    
Chen (2013) C TMT-B ChT < Non-ChT, HC 
Donovan (2005) C TMT-B ns 
Ahles (2010) L D-KEFS Sorting Test ns 
Bender (2006) L TMT-B ns 
Debess (2010) L Concept Shifting Test 1 mos F/U: ChT < Non-ChT 
Hermelink (2007) L TMT-B, RWT Lexical 
Search with Change of 
Category  
ns 
  RWT Semantic Search 
with Change of Category 
Last TX cycle F/U: ChT < 
normative data 
Quesnel (2009) L TMT-B ns 
Tager (2010) L TMT-B ns 
Vearncombe (2009) L D-KEFS Sorting Test ns 
Wefel (2010) L TMT-B 1 mos & 1 yr F/U: ChT < 
normative data 
Wefel (2004) L TMT-B, BCT ns 
Moderate Quality    
Castellon (2004) C TMT-B ns 
Jim (2009) C TMT-B ns 
Kesler (2011) C WCST ChT < Non-ChT, HC 
Nguyen (2013) C TMT-B, IED Shift task ns 
  WCST ChT, Non-ChT < HC 
Schagen (1999) C TMT-B ChT < non-ChT  
Scherwath (2006) C TMT-B ns 
Van Dam (1998) C TMT-B ns 
Wieneke (1995) C TMT-B, BCT ns 
Biglia (2012) L TMT-B ns 
Hurria (2006) L TMT-B ns 
Mar Fan (2005) L TMT-B 1 & 2 yr F/U: ChT < HC 
Mehlsen (2009) L TMT-B ns 
Reid-Arndt (2010) L TMT-B ns 
 34 
Author (Year) 
Study 
Design Measure Resultsa 
Ruzich (2007) L TMT-B, WCST ns 
C. WORKING MEMORY 
High Quality    
Chen (2013) C DSB ChT < Non-ChT, HC 
Ahles (2010) L PASAT ns 
Askren (2014) L VWMT ns 
Bender (2006) L DSB ns 
Collins (2014) L WM composite  Last TX cycle F/U: ChT < HC 
Collins (2009) L WM composite 1 mos F/U: ChT < Non-ChT 
Deprez (2012) L DSB 4 mos F/U: ChT< Non-ChT, HC 
  LNS 4 mos F/U: ChT< Non-ChT, HC 
Hermelink (2007) L DSB ns 
Jenkins (2006) L DSB, LNS ns 
Quesnel (2009) L DSB ns 
Tager (2010) L DSB, LNS, Arithmetic ns 
Wefel (2004) L Arithmetic ns 
Moderate Quality    
Castellon (2004) C PASAT ns 
Deprez (2011) C DSB ns 
Nguyen (2013) C LNS  ChT, Non-ChT < HC  
  Arithmetic ns 
Schagen (1999) C DSB ChT < Non-ChT 
Scherwath (2006) C  DSB ns 
Van Dam (1998) C DSB ns 
Wieneke (1995) C PASAT ChT < normative data 
Dumas (2013) L n-back test ns 
McDonald (2012) L n-back test ns 
Mehlsen (2009) L Arithmetic, DSB, LNS ns 
Ruzich (2007) L Arithmetic, LNS ns 
Low Quality    
Jung (2014) C DSB ChT < HC 
D. PLANNING/DECISION-MAKING 
High Quality    
Chen (2013) C IGT ChT < Non-ChT, HC  
  GDT ns 
Moderate Quality    
Ruzich (2007) L ToL ns 
Low Quality    
De Ruiter (2012) C ToL ChT < Non-ChT 
Note: aResults are presented as impaired functioning. 
BCT=Booklet Category Test; ChT=chemotherapy patients; C=cross-sectional; D-KEFS=Delis-
Kaplan Executive Function System; DSB=Digit Span Backward; F/U=follow-up; GDT=Game of 
Dice Task; HC=healthy controls; IED=Intra/Extradimensional; IGT=Iowa Gambling Test; 
L=longitudinal; LNS=Letter-Number Sequencing; mos= months; non-ChT= non-chemotherapy 
patients; ns= not significant; PASAT=Paced Auditory Serial Addition Test; RWT=Regensburger 
Word Fluency Test; TMT-B=Trail Making Test – Part B; ToL=Tower of London; TX=treatment; 
VWMT=Verbal Working Memory Task; WCST=Wisconsin Card Sorting Test; WM=working 
memory; yr=year. 
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Discussion 
The present review illustrates that a broad range of executive functions has been 
assessed among women with breast cancer using a variety of neuropsychological and 
experimental measures across studies. Most studies examined subcomponents of 
executive functioning using individual measures, although some combined several tasks 
into a composite measure of working memory.  The primary objective of this systematic 
review was to examine subcomponents of executive functioning in women treated with 
chemotherapy for breast cancer. Substantial methodological heterogeneity made it 
difficult to draw definitive conclusions regarding whether some aspects of executive 
functioning are more vulnerable to impairment than others. Inhibition, which was 
primarily assessed using the Stroop task, appears to be least prone to impairment after 
chemotherapy. The other subcomponents of set-shifting, working memory, and 
planning/decision making were inconsistently impaired in patients. In general, deficits 
were more likely to be reported in cross-sectional studies, which is consistent with 
smaller effect sizes found in longitudinal studies reported in meta-analyses examining 
executive functioning (Anderson-Hanley et al., 2003; Ono et al., 2015). Uncontrolled 
practice effects for some tasks in particular (e.g., WCST, ToL) may contribute to the 
failure to detect chemotherapy-related impairment in longitudinal studies with multiple 
assessment points. Although sample size was accounted for in the methodological quality 
assessment, many studies did have relatively small sample sizes. Thus, studies may be 
underpowered to detect subtle effects of chemotherapy on executive functioning.  
Results indicate that inhibition is relatively spared in women treated with 
chemotherapy. Factor analyses of executive functioning suggest that there is no 
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inhibition-specific factor (Friedman et al., 2008; Miyake & Friedman, 2012). Rather, 
inhibition tasks appear to load on a common executive factor (e.g., maintaining an active 
goal and managing that goal when there is interference) which is separable from shifting 
and working memory. It is possible that inhibition was least sensitive to the effects of 
chemotherapy because it was narrowly assessed using the Stroop task, which may not 
represent inhibition as a broader construct. Nigg (2002) also argues that there are eight 
different types of inhibition including interference control, cognitive inhibition, 
behavioral inhibition, oculomotor inhibition, motivational inhibition, and automatic 
inhibition of attention. Within this framework, the Stroop task measures only one aspect 
of inhibition: interference control or prevention of interference due to stimulus 
competition. 
An explanation of why deficits in executive functioning were not consistently 
detected concerns the sensitivity of the tasks, given the subtle nature of chemotherapy-
related cognitive dysfunction (Anderson-Hanley et al., 2003; Falleti et al., 2005). Many 
of the neuropsychological measures of executive functioning discussed above (e.g., 
TMT-B) are primarily used clinically with individuals who have sustained head injuries 
or other damage to prefrontal cortex. Such tests may lack the sensitivity to detect subtle 
impairments in executive functions in women treated with chemotherapy. It may also 
explain why impairments appear to be more evident on tasks of increased complexity 
(e.g., ToL, IGT).  There is emerging evidence that within-person variability in reaction 
time tasks may be a sensitive indicator of cognitive function and useful for providing 
further insights into executive dysfunction in women with breast cancer beyond that of 
mean-level performance (Bernstein et al., 2014). 
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A closer examination of the subcomponents of executive functioning has 
important clinical implications. For instance, executive functioning as a multicomponent 
construct may reveal a specific profile of executive dysfunction characteristic of 
chemotherapy-related impairment. In addition, subcomponents of executive functioning 
may be related to other quality of life outcomes in breast cancer survivors, such as mood 
and daily functioning. Based on the findings from this review, the following 
recommendations for the assessment of executive functioning in the breast cancer 
literature are suggested. With respect to study design, it is important to control for task 
repetition in longitudinal studies using control groups, as many neuropsychological tests 
are prone to practice effects. Consideration should be given to the specific subcomponent 
of executive functioning under investigation, which can facilitate the selection of 
appropriate tasks that specifically tap into those functions. Inclusion of tasks that assess at 
least two different subcomponents is recommended to study executive functioning, and it 
may also be beneficial to include tasks of varying complexity to determine whether 
increased cognitive load affects performance.  
It is important to recognize that within the context of the unity and diversity 
framework (Miyake & Friedman, 2012), the cognitive components of executive 
functioning are dissociable and thus using a single measure of executive ability may not 
fully describe executive functioning. The use of multiple measures for each executive 
function which can be examined individually and as a composite may increase the 
reliability of the executive functioning construct. Composite measures also have an 
advantage of greater power to detect change (Crane et al., 2008). Given the issue of task 
impurity associated with many executive functioning measures, the use of multiple 
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measures allows for aggregation by statistical methods (e.g., latent variable analysis) to 
extract commonalities across tasks and provide a better measure of the intended process 
than any one task alone (Gibbons et al., 2012; Miyake et al., 2000). Working memory 
composites which used five to seven tests appear to be sensitive to detecting change in 
performance associated with chemotherapy treatment that did not emerge when assessed 
by any single test of working memory (Collins et al., 2009; 2014). Thus, it is 
recommended that at least two tasks are included for each subcomponent of executive 
functioning. 
Finally, although neuroimaging findings were not the focus of this review, there is 
evidence of changes in white and gray matter integrity (de Ruiter et al., 2011) and altered 
frontal-subcortical activity, which may underlie poor executive functioning performance 
(Kesler et al., 2011). In particular, changes in task-related brain activation in women 
treated with chemotherapy were noted on set-shifting, planning/decision making, and 
working memory measures despite normal behavioural performance on these tasks 
(Kesler et al., 2011; McDonald et al., 2012). Given these data and discrepant findings of 
chemotherapy-related impairment using traditional measures of central tendency, 
alternative methods to examine executive functioning performance should be considered, 
including within-person variability in performance.  
This review included a rigorous process to ensure collection of all relevant studies 
and did not exclude any studies on the grounds of low quality. Importantly, we evaluated 
studies in terms of methodological quality using an adaptation of predefined criteria 
(Pullens et al., 2010). Although our assignment of individual neuropsychological tests to 
areas of executive functioning was based on conventional distinctions in clinical 
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neuropsychology, there is no gold standard to classify individual tasks, as many executive 
functioning tasks overlap subcomponents.  
In conclusion, this systematic review of the literature revealed that women treated 
with chemotherapy appear relatively less vulnerable to experiencing impairment on tasks 
measuring inhibition, whereas findings were mixed for the other subcomponents of set-
shifting, working memory, and planning/decision making. Findings from 
planning/decision making were based on a small number of studies, thus replications 
using these tasks are needed. Future directions for examining subcomponents of 
executive functioning might include clearly defining the executive process under 
investigation and selecting appropriate tasks and indices to better characterize the nature 
of executive dysfunction. 
Summary 
 In Chapter 2, recommendations were formulated based on the results of the 
systematic review for studying executive functioning in women with breast cancer. In 
keeping with the above recommendations, a computerized Stroop task was selected to 
examine IIV in women diagnosed with breast cancer before (Chapter 3) and after 
(Chapter 4) chemotherapy. Although inhibition was the subcomponent of executive 
functioning that appeared to be the least sensitive to chemotherapy, a closer examination 
using IIV derived from a computerized version of the Stroop task was hypothesized to 
yield additional performance information. Specifically, the Stroop task consists of two 
conditions of varying complexity, which allows examination of the effects of increased 
cognitive load on performance. 
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 In Chapter 3, IIV in women diagnosed with breast cancer is examined in 
accordance with recommendations from the systematic review to include other 
potentially sensitive measures to complement mean performance level. Because IIV is 
posited to reflect lapses in attention and executive control failures (Bunce et al., 1993; 
West et al., 2002), IIV across the entire RT distribution is examined (e.g., all trials, fastest 
trials, slowest trials). The relative sensitivity of IIV in distinguishing patients with breast 
cancer from healthy controls compared to mean performance indicators is also examined. 
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Chapter 3: Pretreatment Differences in Intraindividual Variability 
in Reaction Time between Women Diagnosed with Breast 
Cancer and Healthy Controls 
Publication Status 
 The following chapter is based on the manuscript: Yao, C., Rich, J. B., 
Tannock, I. F., Seruga, B., Tirona, K., & Bernstein, L. J. (2016). Pretreatment 
differences in intraindividual variability in reaction time between women diagnosed 
with breast cancer and healthy controls. Journal of the International 
Neuropsychological Society, 22, 530-539. doi:10.1017/S1355617716000126. 
Abstract 
 Chemotherapy has adverse effects on cognitive performance in women treated for 
breast cancer, but less is known about the period before chemotherapy. Studies have 
focused on mean level of performance, yet there is increasing recognition that variability 
in performance within an individual is also an important behavioral indicator of cognitive 
functioning and underlying neural integrity. Intraindividual variability (IIV) was 
examined prior to chemotherapy and surgery in women diagnosed with breast cancer (n = 
31), and a healthy control group matched on age and education (n = 25). IIV was 
calculated across trials of a computerized Stroop task, including an examination of the 
slowest and fastest trials of reaction time (RT) responses. The groups were equivalent on 
overall accuracy and speed, and participants in both groups were less accurate and slower 
on incongruent trials compared with congruent trials. However, women with breast 
cancer became more variable with increased task difficulty relative to healthy controls. 
Among the slowest RT responses, women with breast cancer were significantly more 
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variable than healthy controls on incongruent trials. This suggests that a specific 
variability-producing process (e.g., attentional lapses) occurs in task conditions that 
require executive control (e.g., incongruent trials). Results are consistent with other 
evidence of executive dysfunction among women treated for breast cancer. These 
findings highlight the importance of pretreatment assessment and show that variability in 
performance provides information about cognition that measures of central tendency do 
not. 
Introduction 
An accumulating body of research demonstrates that chemotherapy has adverse 
effects on cognitive performance in women treated for early breast cancer. Less is known 
about cognitive functioning in the period prior to chemotherapy. Findings from 
prospective longitudinal studies indicate that a subset of women (approximately 20 to 
30%) diagnosed with breast cancer demonstrate cognitive impairment after surgery and 
prior to chemotherapy on neuropsychological tests (Bender et al., 2006; Hermelink et al., 
2007; Jansen et al., 2011; Quesnel et al., 2009; Wefel et al., 2010). Hermelink et al. 
(2007) assessed women diagnosed with breast cancer before both surgery and 
chemotherapy, and reported that 27% of the sample (n = 101) performed poorer than 
expected compared with published normative data for neuropsychological tests. This 
suggests that impairments can be observed prior to any therapy, such as surgery and/or 
exposure to general anesthesia and chemotherapy. Additionally, pretreatment cognitive 
performance was not associated with depression, anxiety, or fatigue (Bender et al., 2006; 
Hermelink et al., 2007), and impairment persists after statistically controlling for these 
factors (Jansen et al., 2011). Recent evidence suggests that other influences including 
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tumor-related factors and comorbidities (Mandelblatt et al., 2014), as well as post-
traumatic stress symptoms (Hermelink et al., 2015) may be related to cognitive 
impairment before any adjuvant treatment. These findings suggest that pretreatment 
impairment may be attributed to a number of factors, such as adverse biological response 
to the cancer itself (e.g., cytokine activity), stress response to having a cancer diagnosis 
(e.g., “battle brain” rather than chemobrain), or pre-existing cognitive vulnerability. 
Functional MRI (fMRI) studies of brain activity when engaged in tasks of 
working memory and response inhibition reveal differences between women who were in 
the period between breast cancer surgery and chemotherapy and healthy controls 
(Cimprich et al., 2010; McDonald et al., 2012; Scherling, Collins, MacKenzie, Bielajew, 
& Smith, 2011; 2012). Notably, although task performance was equivalent between 
patients and controls, the patients showed increased activation in the frontal cortex 
relative to controls, (McDonald et al., 2012; Scherling et al., 2012). Thus, neural activity 
as revealed by fMRI does not necessarily correspond to behavioral task performance. 
Greater cortical activation observed in patients may represent compensatory processes for 
neural dysfunction necessary to achieve performance that is comparable to healthy 
controls. Overall, these studies highlight the importance of characterizing pretreatment 
cognition in women with breast cancer, and indicate that examination of task 
performance does not provide a complete understanding of underlying neural 
dysfunction. 
There is increasing recognition that within-person variability in performance is an 
important behavioral indicator of cognitive function and underlying central nervous 
system integrity. Intraindividual variability (IIV) reflects fluctuations in task performance 
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that occur over short periods of time (Hultsch et al., 2008; Nesselroade, 1991). Numerous 
studies demonstrate that increased IIV in reaction time (RT) is associated with other 
behavioral and functional indices including lower general intellectual level (Jensen, 1992; 
Rabbitt et al., 2001; Strauss et al., 2002), poorer functional capacity in instrumental 
activities of daily living (Burton, Strauss, Hultsch, & Hunter, 2009), and closer proximity 
to death (MacDonald, Hultsch, & Dixon, 2008a). Increased IIV in RT also represents a 
risk factor for declines in cognitive status, including mild cognitive impairment and 
dementia (e.g., Dixon et al., 2007; Hultsch, MacDonald, Hunter, Levy-Bencheton, & 
Strauss, 2000; Murtha, Cismaru, Waechter, & Chertkow, 2002). Furthermore, studies 
demonstrate a relationship between IIV and severity of neurological dysfunction, such 
that greater variability is associated with increasing severity of dementia (Murtha et al., 
2002), and multiple areas of impairment in people with mild cognitive impairment 
(Strauss, Bielak, Bunce, Hunter, & Hultsch, 2007). In contrast, individuals with diseases 
that are not typically linked with neurological symptoms such as arthritis do not show 
increased IIV compared to healthy controls (Hultsch et al., 2000; Strauss et al., 2002). 
The link between IIV and neurological function is relevant for women diagnosed with 
breast cancer given the alterations observed in fMRI studies, which may underlie 
cognitive symptoms. In addition, greater IIV in RT may indicate presence of frontal lobe 
pathology (Stuss et al., 2003), a finding that is relevant to the study of women with breast 
cancer as the frontal cortex appears particularly susceptible to the effects of breast cancer 
and its treatments (for a review see: Anderson-Hanley et al., 2003; 2003). 
IIV was evaluated as a potentially useful marker of cognitive dysfunction in 
women treated for breast cancer (Bernstein et al., 2014). Women with breast cancer 
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treated with chemotherapy and healthy controls were assessed on a simple sustained Go-
No Go attention task, and found group differences under certain conditions. Women with 
breast cancer were more variable than controls at short interstimulus intervals and less 
variable at longer intervals, suggesting greater sensitivity to stimulus presentation rate. 
IIV in that study was conceptualized using the coefficient of variation (CoV), which 
accounts for mean group differences but does not account for potential confounds of age 
or practice on RT. That study provided proof of concept that examination of IIV in 
women diagnosed with breast cancer might be informative for characterizing cognitive 
dysfunction. 
Based on evidence that inhibitory control in women treated for cancer differs 
from healthy controls (Bernstein et al., 2014), as well as fMRI findings reviewed above 
of increased pretreatment activation in the frontal cortex, I hypothesized that pretreatment 
fluctuations in inhibitory control in women diagnosed with breast cancer might be 
expected. Inhibitory control as required in the Stroop task is thought to result from 
attentional/executive control processes that maintain the goals of a task across time and 
control competing pathways, and rely on the prefrontal cortex. Decreased efficiency of 
these processes have been associated with increased IIV, which may be a behavioural 
manifestation of more frequent attentional lapses (Bunce, Warr, & Cochrane, 1993) or 
fluctuations in executive control (Bunce et al., 1993; West et al., 2002) that result in 
lapses of intention (Heilman & Watson, 2012). The Stroop task has been shown to be 
sensitive in distinguishing between normative and pathological aging (Duchek et al., 
2009) and has task conditions that place varying demands on attentional/executive 
control processes.  
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The primary goal of the present study was to examine IIV in women with breast 
cancer before chemotherapy or surgical intervention. A secondary aim was to explore 
possible mechanisms underlying IIV by examining its relationship to demographic, 
clinical and self-report variables. 
Method 
This study is part of an on-going longitudinal investigation of women with breast 
cancer conducted at Princess Margaret Cancer Centre in Toronto, Canada. Only those 
aspects of the method that are relevant to the current study are detailed here. 
Participants 
Participants included women with newly diagnosed breast cancer scheduled to be 
treated with neoadjuvant chemotherapy prior to surgery, most of whom had locally 
advanced breast cancer (n = 31). A group of healthy women (n = 25) matched on age and 
education also participated in the study. All participants were between the ages of 25 and 
65 and fluent in English. Exclusion criteria included impaired color vision, health 
conditions known to be associated with elevated serum levels of cytokines or other 
inflammatory markers (e.g., cardiovascular disease, diabetes, autoimmune systemic 
disease), previous history of other cancer, chemotherapy, psychiatric or neurological 
conditions known to be associated with cognitive deficits (e.g., schizophrenia, dementia, 
stroke), significant history of substance abuse, or current use of psychotropic medication. 
Women attending medical oncology clinics (prior to any cancer treatment) were 
screened for possible inclusion in the study by a clinical trials coordinator. Potentially 
eligible candidates were introduced to the study by their oncologist. If their eligibility 
was confirmed and they gave written informed consent, demographic information was 
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collected first, and then participants completed the objective measures followed by the 
self-report measures described below. Women were compensated $25/hour for their time 
and/or transportation costs for each study visit. This study was approved by the 
University Health Network Research Ethics Board. 
Measures 
Stroop RT task. This task was presented using E-Prime 1.2 software 
(Psychology Software Tools, 2006) on a laptop computer. An external Serial Response 
Box (Psychology Software Tools) was configured with four buttons representing red, 
blue, green, and yellow from left to right and allowed one millisecond accurate RT 
recording. The task was administered individually in a hospital testing room. A single 
word was displayed on the computer screen in one of the four colors (red, blue, green, or 
yellow) against a black background in each trial. Participants responded as quickly and 
accurately as possible by pressing the key on the external response box that corresponded 
to the color of the word. Stroop task instructions are presented in Appendix A. 
The task included three phases: color-to-key acquisition, practice, and test phases. 
Each block began with a message instructing the participant to press any button to begin 
the block of trials. The word appeared after a 1-second delay and remained on the screen 
until a response was made. The color-to-key acquisition phase was designed to establish 
strong mapping between stimulus color and the corresponding response keys. Each of the 
four colors was presented 10 times in random order in the form of “XXXX” in a single 
block of 40 trials. The practice and test phases consisted of both congruent and 
incongruent trials. On congruent trials, the words were written in the color corresponding 
to the meaning of the word (e.g., “RED” written in red). On incongruent trials, the words 
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were displayed in a color that did not match the meaning (e.g., “BLUE” written in red). 
Practice trials were presented in one block of 24 trials, and test trials were presented in 
four blocks of 96 trials with 48 congruent trials and 48 incongruent trials randomly 
intermixed in each block. Between blocks of trials, participants could take a break before 
initiating the next block of trials by pressing any response button. Response times were 
recorded as the time between the onset of the stimulus on the screen and the response 
recorded by the computer. The dependent measures were accuracy and reaction time 
responses calculated separately for congruent and incongruent test trials.  
Self-reported measures. To investigate other potential pretreatment differences, 
participants completed self-report questionnaires evaluating mood, fatigue, and cognitive 
symptoms. 
Mood. The Hospital Anxiety and Depression Scale (HADS) is a 14-item self-
reported measure designed to assess depression and anxiety symptoms in patients with 
medical conditions (Zigmond & Snaith, 1983), and has been shown to be valid and 
reliable for use in people with cancer (Moorey et al., 1991). It contains two 7-item 
subscales assessing frequency of depression and anxiety over the previous week. Higher 
scores indicate more distress (maximum score for each scale is 21). HADS questionnaire 
is presented in Appendix B. 
Fatigue. The Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-
F) is a validated 13-item measure of fatigue in cancer patients (Yellen, Cella, Webster, 
Blendowski, & Kaplan, 1997). Participants rate the frequency of fatigue-related 
symptoms (five items) or activity-related consequences of fatigue (eight items) over the 
past week on a 5-point scale. Eleven of the items are negatively worded (e.g., “I feel 
 49 
weak all over”). The two positively worded items (e.g., “I have energy”) are reverse 
scored. Higher scores reflect more fatigue. FACIT-F questionnaire is presented in 
Appendix C. 
Cognitive function. The Functional Assessment of Cancer Therapy Cognitive 
Scale – Version 3 (FACT-Cog 3) is a 37-item measure designed to evaluate self-reported 
cognitive impairment in cancer patients (Wagner, Sweet, Butt, Lai, & Cella, 2009). The 
FACT-Cog 3 assesses cognitive impairment (20 items), comments from others (4 items), 
cognitive ability (9 items), and impact on quality of life (4 items). Participants rate the 
frequency with which each statement has occurred over the past week on a 5-point scale. 
Positively worded items were reverse scored so that higher total scores reflect more 
cognitive problems. FACT-Cog 3 is presented in Appendix D. 
Data Preparation 
RT data were prepared prior to calculation of IIV measures to be consistent with 
previous approaches (Hultsch et al., 2000; 2008). Significant group differences in mean 
level of performance are often positively associated with differences in SD values. Thus, 
IIV may be large in women with breast cancer because their mean RT is larger than 
healthy controls. In addition, systematic changes across trials may also be present (e.g., 
practice, learning effects). Therefore, it is recommended that these systematic effects be 
removed from RT data prior to calculating measures of IIV (Hultsch et al., 2000; 2002). 
The distribution of raw latency scores was first examined at the level of individual trials. 
Outliers with extremely slow or fast responses that might reflect error (e.g., accidental 
key press, task interruption) were excluded. A lower bound for valid responses was set at 
150 ms based on minimal RTs suggested by prior research on four-choice RT measures 
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(Strauss et al., 2007). An initial upper bound was determined based on examination of 
frequencies of RTs (i.e., 4,000 ms), and extreme outliers were excluded relative to the 
rest of the sample. A subsequent upper bound was based on computing the mean and 
standard deviation separately for each group and task condition (congruent and 
incongruent) and dropping any trials exceeding the mean by three or more standard 
deviations. The percentage of trials excluded across the entire Persons by Trials data 
matrix was 2.04%. The procedure of excluding outlying data points represents a 
conservative approach to examining IIV as this method underestimates variability 
somewhat. 
Intraindividual standard deviation (ISD) scores. IIV was indexed by 
computing the ISD scores across correct response latency trials of congruent and 
incongruent conditions of the Stroop task (Hultsch et al., 2000; 2008). To control for age 
and group as well as systematic changes associated with practice, a regression procedure 
was used to adapt the RT data prior to calculating ISDs. Using a Person by Trial matrix, 
data were corrected for the effects of age, group, trial and their higher order interactions 
to yield adjusted residual scores: 
y = a + (age)b + (group)c + (trial)d + (age x group)e + (age x trial)f + (group x 
trial)g + (age x group x trial)h + e 
This process (Hultsch et al., 2000; 2008) yields scores that can be subsequently 
converted to T-scores to facilitate interpretation. Larger scores indicate relatively uneven 
performance across trials, whereas smaller ISD scores reflect a more consistent 
performance. 
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Slowest/fastest ISD scores. Adapting methodology from the literature on age-
related differences in RT distributions (Hultsch et al., 2002; Salthouse, 1993), further 
analyses were conducted to differentiate variability within the slowest RT trials from all 
responses. If increased IIV in RT reflects attentional lapses resulting from reduced 
attention/executive efficiency, then long RTs and a positive skew in the RT distribution 
should be observed. Thus, group differences should occur only in the slowest RT trials 
and even after controlling for variability in the fast trials. ISDs corrected for effects of 
age, group, and trial were calculated for the trials that fell within the 20th (slowest) and 
80th (fastest) percentile of the RT distribution. 
Statistical Analyses 
RT data preparation was performed with IBM SPSS Statistics 22.0. All 
subsequent statistical analyses used SAS 9.4. Independent samples t-tests and Fisher’s 
exact tests were used to assess differences between groups at baseline. To assess 
interactions of task condition and group, separate mixed effects model analyses were 
computed for each Stroop performance variable (i.e., accuracy, mean RT and ISD for all, 
fast, and slow trials). Alpha levels of p < .05 were set as the threshold to indicate 
statistical significance. A final set of analyses used Pearson correlations to compare 
Stroop performance variables, self-report measures, demographic (i.e., age and 
education), and clinical characteristics (i.e., days since diagnosis). To account for 
multiple comparisons, a threshold of p < .001 was used for the resulting correlations. 
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Results 
Participant Characteristics 
Table 5 summarizes demographic, clinical, and self-report characteristics of 
women with breast cancer and healthy controls. Total HADS scores and HADS Anxiety 
subscale scores were higher for women with breast cancer (ps < .01). More women with 
breast cancer expressed clinically significant levels of anxiety (i.e., score > 7) compared 
to controls (see Table 1). There were no significant differences in age, education, HADS 
Depression subscale, FACIT-Fatigue, or FACT-Cog 3 scores between groups. 
 
Table 5. Participant Demographic, Clinical, and Self-report Characteristics 
 
Variable 
Patients (n = 31) 
M (SD) 
Controls (n = 25) 
M (SD) 
 
p 
Age, years 46.1 (8.7) 46.1 (11.0) .98 
Education, years 15.3 (2.1) 15.8 (2.1) .38 
Breast cancer stage 
   I 
   II 
   III 
   IV  
 
n = 1 
n = 5 
n = 24 
n = 1 
 
– 
– 
– 
– 
 
– 
– 
– 
– 
Days since diagnosis 32.5 (23.9) – – 
HADS Total 12.7 (7.4) 7.8 (6.5) .01 
HADS Depression subscale 4.2 (3.9) 2.6 (3.0) .10 
   Normal  n = 26 n = 22 .72a 
    Mild n = 1 n = 2 
   Moderate n = 3 n = 1 
   Severe n = 1 n = 0 
HADS Anxiety subscale 8.5 (4.8) 5.1 (3.9) .007 
   Normal n = 13 n = 20 .01a 
    Mild n = 7 n = 3 
   Moderate n = 8 n = 1 
   Severe n = 3 n = 1 
FACIT – Fatigue 12.5 (9.8) 9.7 (8.7) .26 
FACT – Cog 3   40.2 (26.5)b 29.3 (17.7) .08 
Note. HADS=Hospital Anxiety and Depression Scale; FACT=Functional Assessment of Cancer Treatment; 
FACIT=Functional Assessment of Chronic Illness Therapy Fatigue. 
a Fisher exact test compared frequency of normal and clinically significant levels of affective distress. 
b n = 30 due to incompletion of FACT- Cog 3. 
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Table 6. Participant Performance Variables on the Stroop Task 
 Stroop Congruent Trials   Stroop Incongruent Trials   Group-Task Condition Interaction 
Variable Patients (n =31) Controls (n =25) pa  Patients (n =31) Controls (n =25) pa  F p η2 
Accuracyb, % 99.28 (0.74) 98.96 (1.31) .26  97.56 (2.04) 96.67 (3.84) .30   .61 .44 .007 
Mean RTb, ms 808.17 (171.14) 752.27 (107.89) .14  966.31 (228.11) 885.03 (147.34) .11  1.71 .20 .006 
Mean RT – fastest, ms 574.62 (119.00) 535.53 (86.21) .17  580.59 (132.93) 534.64 (87.85) .13  1.43 .24 .03 
Mean RTb – slowest, ms 1251.99 (263.09) 1172.75 (175.30) .20  1333.27 (319.64) 1225.58 (190.16) .12  2.83 .10 .02 
ISDb 7.46 (1.99) 6.96 (1.36) .29  9.78 (2.60) 8.87 (1.67) .12  1.44 .24 .007 
ISD - fastest 2.20 (0.84) 1.98 (0.53) .24  2.23 (0.90) 2.03 (0.62) .35   .02 .88 .00 
ISDb - slowest 5.19 (1.52) 5.41 (1.34) .58  8.16 (1.79) 7.03 (1.40) .01  7.82 .007 .05 
Note. Values in parentheses are standard deviations; RT=Reaction Time; ISD=Intraindividual Standard Deviation. 
a Paired t test p-value. 
b Significant main effect of task condition at ps < .001.  
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Stroop Mean Level Performance 
 Differences as a function of condition (congruent vs. incongruent) and group 
(women with breast cancer vs. healthy controls) were examined using 2 (group) by 2 
(condition) mixed-model ANOVAs on accuracy and mean RT: all, fastest, and slowest 
trials (Table 6). Both breast cancer and healthy control groups performed at a very high 
level on the Stroop task (mean accuracy > 96%). There was a significant main effect of 
condition on accuracy and mean RT for all and slowest trials, such that participants were 
less accurate and slower on the incongruent trials compared to congruent trials. No 
significant group effects or group by condition interactions were observed on Stroop 
accuracy or mean RT scores. 
Stroop IIV Performance 
A mixed-model ANOVA revealed a significant interaction between groups and 
performance on congruent vs. incongruent trials of the Stroop task (p < .01; see Table 6). 
Independent samples t-tests showed that women with breast cancer were significantly 
more variable than healthy controls on the slowest trials in the incongruent condition (p < 
.01). Responses of women with breast cancer became more variable with increased task 
difficulty, whereas variability did not change as much with task difficulty in healthy 
controls. The interaction remained significant even after controlling for group differences 
in speed of performance (i.e., mean RT of the slowest trials), F(1, 52) = 5.30, p = .03, η2 
= .03. No significant interaction effects were observed between groups and performance 
on the fastest trials and across all trials.1 Figure 2 displays RTs from the slow portion of 
the distribution for each participant with the incongruent condition. Using procedure 
                                                
1 Data analyses were performed on the final block of the Stroop task (i.e., last 96 trials), which served as a 
proxy for successful acquisition of key/color mapping and effort by the end of the task. The pattern of 
results for the last 96 trials was identical to results based on all trials. 
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recommended by Hultsch et al. (2002), a one-way analysis of covariance (ANCOVA) 
was conducted to examine group differences in the slowest trials in the incongruent 
condition while controlling for the effects of the fastest trials. The magnitude of the group 
effect observed in the uncontrolled analysis was retained, F(1, 53) = 5.82, p = .01, η2 = 
.09. 
Potential Covariates 
Table 7 shows the correlations between demographic, clinical, self-report 
characteristics and select Stroop performance variables for all participants. Across all 
participants, FACT-Cog 3 scores were not significantly correlated with congruent or 
incongruent trials on accuracy, mean RT (all, fastest, and slowest trials), or ISD (all, 
fastest, and slowest trials), although they were significantly related to HADS Depression, 
HADS Anxiety, and FACIT-Fatigue scores (ps < .001). That is, women who reported a 
greater number of depressive, anxiety, and fatigue symptoms also reported more 
cognitive problems. Age was correlated with mean RT and accuracy; older women were 
slower across conditions but more accurate on congruent trials. Otherwise, education, 
days since diagnosis, HADS Anxiety, HADS Depression or FACIT-Fatigue scores were 
unrelated to Stroop performance.  
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Figure 2. Stroop Residual T-Scores of the Slowest RT Responses across Incongruent 
Trial Items for Each Participant in Patient and Healthy Control Group
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Table 7. Pearson Correlations of Demographic, Clinical, Self-Reported Measures, and Stroop Performance Variables For Patients and 
Controls (n = 56) 
 
Note. a Analyses performed on patient group only (n = 31); *p < .001; Con. = congruent condition; Incon. = incongruent condition; FACIT-F=Functional 
Assessment of Chronic Illness Therapy-Fatigue; FACT=Functional Assessment of Cancer Treatment; HADS-A=Hospital Anxiety and Depression Scale-Anxiety 
Subscale; HADS-D=Hospital Anxiety and Depression Scale-Depression Subscale; ISD = intraindividual standard deviation.; RT = reaction time.
 
Age Education 
Days 
Since 
Diagnosisa 
FACT-
Cog 3 
HADS-
A 
HADS-
D 
FACIT
-F 
Accuracy 
(Con.) 
Accuracy 
(Incon.) 
Mean RT 
(Con.) 
Mean RT 
(Incon.) 
ISD-
Slowest 
(Con.) 
ISD-
Slowest 
(Incon.) 
Age 
 
1.00             
Education 
 
0.27 1.00            
Days Since 
Diagnosisa 
-0.01 -0.30 1.00        
 
   
FACT-Cog 3 
 
0.01 0.23 -0.25 1.00          
HADS-A 
 
-0.15 0.23 -0.19    0.50* 1.00         
HADS-D 
 
-0.08 0.09 -0.22    0.49*    0.59* 1.00        
FACIT-F 
 
-0.25 0.11 -0.29    0.52*    0.43*    0.71* 1.00       
Accuracy 
(Con.) 
0.44* -0.05 -0.13 0.14 0.06 0.15 0.06 1.00      
Accuracy  
(Incon.) 
0.05 0.22 0.08 -0.002 0.25 0.29 0.16 0.40* 1.00     
Mean RT 
(Con.) 
0.43* -0.29 -0.02 0.09 -0.07 0.006 -0.11 0.42* -0.02 1.00    
Mean RT 
(Incon.) 
0.42* -0.23 -0.03 0.06 -0.11 -0.06 -0.12 0.44* -0.10 0.95* 1.00   
ISD-slowest 
(Con.) 
-0.08 0.03 -0.12 -0.03 -0.16 -0.07 0.06 0.01 0.05 -0.30 -0.32* 1.00  
ISD-slowest 
(Incon.) 
-0.13 0.24 -0.12 0.23 0.11 0.02 0.17 -0.01 -0.06 0.20 0.20 0.28 1.00 
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Discussion 
The primary objective of this study was to examine IIV in RT on an inhibitory 
control task in women with breast cancer prior to any treatment. There were no 
differences between groups on overall accuracy, mean RT or variability; however, 
patients demonstrated greater variability in their performance compared to healthy 
controls as the difficulty of the task increased and greater executive control was required. 
Consistent with other studies that have examined IIV and various health and neurological 
conditions (Burton et al., 2006; de Frias et al., 2012; Fuentes, Hunter, Strauss, & Hultsch, 
2001; Hultsch et al., 2000), our results suggest that IIV is more sensitive than a measure 
of central tendency (mean RT) for detecting differences in cognitive performance 
between patients and healthy controls. Specific to the breast cancer population, the 
current data are also in keeping with our prior study in which examination of IIV 
revealed that on a test of sustained attention requiring inhibitory control, patients had 
greater IIV at faster stimulus presentation rate, suggesting that they are more variable 
with increased cognitive load (Bernstein et al., 2014). Thus, IIV appears to provide an 
important behavioral measure of function even at pretreatment assessment. 
Results show that group differences varied across the RT distribution, such that 
women with breast cancer were more variable in the slow portion of the RT distribution 
on incongruent trials of the task, but variability was equivalent between groups on the 
congruent trials and in the fast portion of the RT distribution. IIV appears to result from a 
specific variability-driving process, such as attentional lapses, present only at the slow 
end of the RT distribution under conditions that require increased inhibitory control. Our 
results are consistent with reports within the aging literature that demonstrate IIV in RT 
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changes across task conditions that require increased executive control. For example, 
performance variability is greater for older adults compared to younger adults under task 
conditions requiring active recruitment of executive processes (West et al., 2002), 
probably because decreased attentional resources associated with aging results in more 
fluctuations in executive control. These fluctuations produce longer RTs, increase the 
variability of an individual’s performance, and lead to greater positive skew in the RT 
distribution of older adults. Such findings have been described as failures of attention or 
intention within the IIV and cognitive aging literature. Although attention and intention 
may be subserved by different neural networks (with greater involvement of the parietal 
lobes for attention and of the frontal lobes for intention), they nevertheless share 
reciprocal connections (Heilman & Watson, 2012) and are likely overlapping constructs. 
The findings obtained from the Stroop task used in this study primarily reflect lapses of 
attention, which resulted in higher IIV in the slowest trials in the incongruent trial for the 
breast cancer group despite highly accurate overall performance across all participants. 
If IIV is a marker of neural integrity, then our results indicate that the biological 
or psychological response to breast cancer diagnosis may have adverse effects on brain 
function. Results show that women with breast cancer reported more anxiety compared to 
controls but anxiety was not related to mean RT or ISD measures. Hermelink et al. (2007; 
2015) suggested that cognitive impairment seen prior to neoadjuvant treatment may be 
related to stress-response symptoms that do not necessarily coincide with symptoms of 
depression and/or anxiety. Persistent stress-response symptoms may have adverse effects 
on neurological functioning and behavior in high cognitive-demand circumstances. The 
finding of differences between patients and controls prior to treatment is important to 
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better understand the long-term cognitive impairment associated with breast cancer and 
its treatment; any pretreatment deficits may be compounded by the neurotoxic effects of 
chemotherapy. 
The source of performance variability has been attributed to both neurobiological 
(e.g., disruptions or damage to neural networks) and behavioral (e.g., fluctuations in 
affective state) factors (Montgomery, 1995). Previous research suggests that affective 
influences are more likely to impact IIV that is measured across longer time periods (e.g., 
hours, days or weeks). In contrast, changes in neural integrity are more likely to affect 
IIV that is measured over shorter intervals, such as the present trial-to-trial RT data 
(Hultsch et al., 2000; Strauss et al., 2002). Given the substantial psychological distress 
associated with breast cancer diagnosis and treatment, IIV may also be a useful measure 
in that it is primarily sensitive to neurological changes rather than affective states. 
A methodological strength of this study is the computation of IIV that controls for 
the systematic effects of age, group, and practice that could impact mean RT. In addition, 
the slowest and fastest RT responses were examined to address potential variability-
driving mechanisms. Another strength of this study is recruitment of women with breast 
cancer who were scheduled to undergo neoadjuvant chemotherapy followed by surgical 
treatment, which provided an opportunity to examine pretreatment cognitive 
performance. In contrast, most studies of breast cancer patients prior to chemotherapy are 
conducted after surgery (e.g., mastectomy, lumpectomy; Cimprich et al., 2010; 
McDonald et al., 2012; Scherling et al., 2011; 2012). 
 Limitations of our study include an inability to rule out pre-existing cognitive 
vulnerabilities that might contribute to pretreatment group differences (e.g., stress 
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response). Secondly, the standardized effects were small and in the range of η2 = .03 to 
.09. although they are comparable to those reported in other studies examining executive 
function in comparison to controls (see: Anderson-Hanley et al., 2003; 2003; Ono et al., 
2015). Statistical power was low in this study due to a relatively small sample size and 
small effects, which may explain there was no group effect in IIV across all trials or no 
influence of potential covariates (e.g., age, education, days since diagnosis, other self-
report indices). However, there was sufficient power to detect IIV differences at the 
group level in the slowest RT responses, consistent with a priori hypotheses. The present 
study is also limited by the examination of a single measure of intraindividual variability. 
Although performance on the congruent condition of the Stroop task was contrasted with 
the incongruent condition, the inclusion of tasks assessing other domains (e.g., semantic 
or lexical decision) would strengthen the view that executive functioning is selectively 
impaired in women newly diagnosed with breast cancer. Lastly, although our patients and 
controls were equivalent in education level, both groups were composed of well-educated 
women, which limit the generalizability of the results to populations with a fuller range 
of educational attainment. 
In future studies, it will be important to replicate these findings in a larger and 
more diverse sample. It will also be important to examine IIV and change in cognitive 
function following adjuvant treatments, which will be examined in the following chapter. 
Additional task manipulations to investigate other aspects of executive function (e.g., 
working memory, task switching) would be useful in providing additional information on 
the nature of cognitive impairment. An important question is whether pretreatment IIV 
can predict cognitive functioning after breast cancer treatment. Such information might 
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help identify those at risk and inform treatment options for those individuals. Further 
elucidation of the mechanisms that drive differences in IIV should be examined as well. 
If differences in IIV are due to a persistent stress-based response, then the inclusion of 
objective measures of stress (e.g., basal cortisol levels, cortisol reactivity to stress) will 
contribute to better understanding of pretreatment cognitive impairment. Additionally, if 
pretreatment cognitive impairment results from a biological response to the cancer itself, 
then examining associations to cancer stage would be important, which was not possible 
to examine because of homogeneity in the sample. 
 The present study provides evidence that untreated women with breast cancer 
have greater IIV when performing cognitive tasks that require inhibitory control than do 
healthy controls. In particular, conditions demanding increased load on the executive 
system produced greater variability in patients than healthy controls, even after 
controlling for affective distress. Our results highlight the importance of examining IIV 
in addition to measures of central tendency to better understand the subtle nature of 
cognitive impairment in women with breast cancer. It would be worth exploring if IIV is 
a reliable indicator of cognitive change due to breast cancer and its treatments in other 
tasks. If it is, then this measure of variability holds promise as a predictor of cognitive 
change. Furthermore, the results have methodological implications for the design and 
analysis of future studies, namely to include pretreatment assessment, tasks that vary in 
executive control demands, measures of variability, and larger and more diverse patient 
populations. 
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Summary 
 Chapter 3 provided evidence that untreated women with breast cancer have 
greater IIV when performing cognitive tasks that require inhibitory control than do 
healthy controls. In particular, conditions demanding increased load on the executive 
system produced greater variability in patients than healthy controls, even after 
controlling for factors such as practice, learning effects, and group-level differences in 
mean performance. IIV in performance was not related to age, education, days since 
diagnosis, self-reported cognitive symptoms, or affective distress. Furthermore, IIV 
revealed differences between women with breast cancer and healthy controls that mean 
performance level measures did not. 
 Thus far, evidence suggests that IIV is an important indicator of cognitive 
function. Because many cognitive symptoms in women with breast cancer have been 
attributed to the effects of chemotherapy, the following chapter examines IIV in Stroop 
performance by observing the same cohort of women after neoadjuvant chemotherapy. 
Additional analyses examine changes in self-reported cognition across two self-report 
questionnaires and their relationship to change in objective Stroop performance.  
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Chapter 4: Intraindividual Variability in Reaction Time Before 
and After Neoadjuvant Chemotherapy in Women Diagnosed with 
Breast Cancer 
Publication Status 
 The following chapter is based on a manuscript submitted for publication: Yao, 
C., Rich, J. B., Tirona, K., & Bernstein, L. J. Intraindividual Variability in Reaction Time 
Before and After Neoadjuvant Chemotherapy in Women Diagnosed with Breast Cancer.  
Abstract 
 Women treated with chemotherapy for breast cancer experience subtle cognitive 
deficits. Research has focused on mean performance level, yet recent work suggests that 
within-person variability in reaction time (RT) performance may underlie cognitive 
symptoms. We examined intraindividual variability (IIV) in women diagnosed with 
breast cancer and treated with neoadjuvant chemotherapy. Women with breast cancer (n  
= 28) were assessed at baseline before neoadjuvant chemotherapy (T1), approximately 1 
month after chemotherapy but prior to surgery (T2), and after surgery about 9 months 
post chemotherapy (T3). Healthy women of similar age and education (n = 20) were 
assessed at comparable time intervals. Using standardized regression-based approach, we 
examined changes in mean performance level and IIV on a Stroop task and self-report 
measures of cognitive function from T1 to T2 and T1 to T3. At T1, women with breast 
cancer were more variable than controls as task complexity increased. Change scores 
from T1 to T2 were similar between groups on all Stroop performance measures. From 
T1 to T3, healthy controls improved more than women with breast cancer. IIV was more 
sensitive than mean RT in capturing group differences. Additional analyses showed 
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increased cognitive symptoms reported by women with breast cancer from T1 to T3. 
Specifically, change in language symptoms was positively correlated with change in 
variability. Women with breast cancer have declines in attention and inhibitory control 
relative to pretreatment performance. Future studies should include measures of 
variability, as they are an important, sensitive indicator of change in cognitive function. 
Introduction 
The previous study demonstrated pretreatment differences of greater IIV in 
women diagnosed with breast cancer compared to healthy controls as task difficulty 
increased and attentional control was required. These results show that IIV is a sensitive 
marker of pre-existing differences between women with breast cancer and healthy 
individuals. It is important to understand whether there are changes in variability 
following breast cancer treatment, as women treated with chemotherapy commonly 
report cognitive difficulties (Hutchinson, Hosking, Kichenadasse, Mattiske, & Wilson, 
2012; Pullens et al., 2010).  
Cancer-related cognitive impairment is multifaceted and can be influenced by 
factors such as the disease itself, stress and mood disturbances, and other adjuvant 
therapies. Prospective longitudinal studies reveal that a proportion of women diagnosed 
with breast cancer may demonstrate impaired neuropsychological test performance 
before receiving chemotherapy (Hermelink et al., 2007; Jansen et al., 2011). Most 
longitudinal studies show that cognitive deficits emerge during (Collins, MacKenzie, 
Tasca, Scherling, & Smith, 2013b) and immediately following chemotherapy (Brezden et 
al., 2000; Hermelink, 2010; Stewart et al., 2008; Tchen et al., 2003) and tend to resolve 
over time (Collins et al., 2014; Wefel, Lenzi, Theriault, Davis, & Meyers, 2004a), 
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although some indicate persistent, progressive, or delayed onset of deficits one year post 
chemotherapy (Collins et al., 2014; Wefel et al., 2010). In general, effects obtained from 
longitudinal studies when pretreatment level of performance is accounted for are weaker 
than those reported in cross-sectional studies, which underscores the subtlety of changes 
in cognition associated with breast cancer and its treatments (Bender et al., 2006; Shilling 
et al., 2005; Wefel, Lenzi, Theriault, Davis, & Meyers, 2004a). 
Research in neuropsychological assessment has traditionally overlooked within-
person variability in performance. Instead, cognitive abilities are typically measured by 
mean performance level and treated as trait-like dimensions of individual functioning. 
However, intraindividual variability (IIV) or trial-to-trial fluctuations in reaction time 
(RT) tasks are of sufficient magnitude to be theoretically and practically important 
(Eizenman, Nesselroade, Featherman, & Rowe, 1997; Hultsch et al., 2000; Strauss et al., 
2002). For example, higher levels of IIV have been associated with age-related decline 
and poorer performance across multiple cognitive domains (Bielak, Hultsch, Strauss, 
MacDonald, & Hunter, 2010a; 2010b; MacDonald et al., 2003). Moreover, IIV offers 
predictive utility for cognitive status in older adults (de Frias et al., 2012; Dixon et al., 
2007; Hultsch et al., 2000). 
IIV appears to be useful in the detection of subtle cognitive deficits associated 
with breast cancer and its treatment. For example, breast cancer survivors treated with 
chemotherapy 1 year earlier were more variable compared with healthy controls under 
specific task conditions on a measure of simple sustained attention involving short inter-
stimulus intervals (Bernstein et al., 2014). Increased IIV has been attributed to more 
frequent attentional lapses (Bunce et al., 1993) or fluctuations in cognitive control (West 
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et al., 2002). Thus, the elevated IIV observed among women treated for breast cancer 
may reflect disruptions in allocation of attention or cognitive control. 
The current study was designed to examine IIV and mean performance level on 
the same Stroop RT task longitudinally in women newly diagnosed with breast cancer 
and in healthy controls. Our primary aim was to determine if performance on those 
measures differs over time between groups. A secondary aim was to examine self-
reported cognitive function at the same time points in relation to objective measures of 
cognition. 
Methods 
Participants 
The same sample of women diagnosed with breast cancer and scheduled to 
receive neoadjuvant chemotherapy and healthy controls were followed after pretreatment 
assessment. We recruited 28 women with breast cancer and 20 healthy controls to the 
study. Attrition rates ranged from 4-12% and did not differ between patient and control 
group (p = .31). One patient died and three controls did not continue in the study.2 Table 
8 presents demographic and clinical characteristics of each group. Age and education 
were equivalent across groups. 
 For a full description of the participants including exclusion criteria, see Chapter 
3 Methods section. 
  
                                                2"A technical problem with the Serial Response Box resulted in missing data from two patients and two 
controls not attributable to participant drop out. To maximize the number of participants included in the 
analyses, those who missed a single assessment due to problems with task apparatus were included in the 
study. The pattern of results did not differ between women who missed one assessment and those who 
completed all three assessments. "
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Table 8. Demographic and Clinical Characteristics of Patient and Control Groups 
 
Characteristic 
Patients 
(n = 28) 
Controls 
(n = 20) p d 
Age at baseline, years 45.3 (8.5) 45.7 (11.3) .90 .04 
Education, years 15.4 (2.2) 15.6 (2.3) .75 .09 
Stage of disease     
   I n = 1    
   II n = 5    
   III n = 21    
   IV n = 1    
Type of Chemotherapy     
   AC-P n = 4    
   FEC n = 20    
   AC-D/T n = 1    
   TCH n = 1    
   Docetaxel n = 1    
   Unknown n = 1    
 T2 T3    
No. of patients who had 
started on hormone 
therapy prior to T2 or T3 
assessment 
0 (0%) 19 (76%)    
Note. Values in parentheses are standard deviations. 
AC-P = Doxorubicin, cylcophosphamide, paclitaxel; FEC-D = Fluorouracil, epirubicin, cyclophosphamide, 
docetaxel, trastuzumab; AC-D/T = Doxorubicin, cyclophosphamide, docetaxel; TCH = Docetaxel, 
carboplatin, trastuzumab; T2 = Time 2; T3 = Time 3.  
 
Procedure 
 
All participants completed a baseline assessment, which included a computerized 
RT Stroop task and self-report questionnaires to assess symptoms of depression, anxiety, 
fatigue, and cognitive dysfunction. Baseline (T1) was completed before surgery and 
chemotherapy for women diagnosed with breast cancer. Further assessment was 
undertaken approximately 1 month after chemotherapy but prior to surgery (T2), and 
again after surgery and 9 months post chemotherapy (T3). The healthy control group was 
also tested three times at comparable intervals.  
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Measures 
RT task. The same Stroop RT task used in the previous study was also employed 
here (see Chapter 3 Methods for a full description of the task).  
Self-report measures. Participants completed the same self-report questionnaires 
evaluating mood, fatigue, and cognitive symptoms as previously reported in Chapter 3 
(see Methods section details). In addition to the FACT-Cog 3, participants completed an 
additional measure of self-reported cognition. The Patient’s Assessment of Own 
Functioning Inventory (PAOFI) includes 33 items which measure cognitive functions in 
everyday life (Chelune, Heaton, & Lehman, 1986), and has been found to be useful in 
identifying domain-specific cognitive symptoms in women with breast cancer (Bender et 
al., 2006; Ganz et al., 2013). The inventory consists of four subscales: memory (10 
items), language and communication (9 items), sensorimotor skills (5 items), and higher-
level cognition (9 items). Each item response was given on a 6-point scale. Subscale 
scores and a total summed score were calculated, with higher scores indicating greater 
everyday cognitive difficulties. To examine clinical significance, participants were 
categorized as having “high complaints” if their score was > 1 SD above the mean of the 
healthy controls (Ganz et al., 2013). PAOFI questionnaire is presented in Appendix E. A 
decrease of 10.6 points in the total FACT-Cog 3 score is considered clinically significant 
change (Cheung et al., 2014). 
RT Data Preparation 
An established procedure (Hultsch et al., 2000; 2008) was used to prepare the RT 
data prior to calculation of variability measures described previously in Chapter 3. IIV 
was indexed by computing the intraindividual standard deviation (ISD) scores across 
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correct response latency trials of congruent and incongruent conditions, which was also 
described in the previous study. To summarize, ISD scores were calculated for each task 
condition (congruent and incongruent) across (a) all RT trials and (b) the fastest and 
slowest RT trials (within the 20th and 80th percentile of the RT distribution), which were 
then converted to T-scores to facilitate interpretation. The examination of the fastest and 
slowest RT trials provides information about the source of variability.  
Statistical Analyses 
A planned sample size of 31 patients and 31 controls was selected to provide 80% 
power (Type I error of 5% and two-sided tests) to detect medium effect sizes based on 
previous studies (Anderson-Hanley et al., 2003). It was estimated that 26 patients and 26 
controls would be available for assessment at 1-year follow-up based on retention rates 
reported in other studies (Collins et al., 2009; Jenkins et al., 2006).  
To assess individual change in Stroop performance (e.g., accuracy, mean RT and 
IIV) and self-reported cognition (e.g., PAOFI, FACT-Cog 3) across the two assessment 
intervals (T1-T2 and T1-T3), we used a standardized regression-based (SRB) approach, 
which has been employed in other longitudinal neurocognitive studies in cancer 
populations (Collins et al., 2009; Stewart et al., 2008). This approach, recommended for 
the study of cancer-related cognitive change (Duff, 2012; Ouimet, Stewart, Collins, 
Schindler, & Bielajew, 2009), has several advantages, including accounting for factors 
that may affect outcomes, such as demographic and mood-related variables and 
regression to the mean (Sawrie, Marson, Boothe, & Harrell, 1999). Using SRB 
methodology on both Stroop and self-report measures of cognitive function provides a 
common metric to facilitate comparison across assessment tools (Martin, Griffith, 
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Sawrie, Knowlton, & Faught, 2006; McSweeny, Naugle, Chelune, & Lüders, 1993). 
Candidate variables including age and education, as well as change in HADS Depression 
and Anxiety scores and change in FACIT-F scores were included in the model in a 
stepwise fashion using p = .05 as the criterion for entrance and p = .10 as criterion for 
removal. Data from the control group were used to construct the regression equation 
predicting retest scores (i.e., T2 or T3) from baseline (T1) scores. SRB change scores for 
each participant were computed by subtracting the predicted from the observed retest 
score on each measure and dividing by the standard error of the estimate in the control 
group. These change scores represent the extent to which the observed change on each 
measure deviated from that expected on the basis of practice and measurement error 
alone. 
 Independent sample t-tests were used to assess group differences in baseline and 
change scores across T1-T2 and T1-T3. Mixed ANOVAS were also used to test the 
interactions between task condition and group on Stroop performance variables. To 
increase comparability between the current study and previous research, classification of 
women who declined or did not decline (remained stable or improved) was calculated 
such that any SRB change score exceeding ± 1.96 represented statistically significant 
change. Pearson correlations measured the associations between change in Stroop 
performance measures and change in self-report cognitive measures. Because of the 
multiple planned analyses, the statistical significance cutoff was set a priori at p < .01 for 
all analyses.  
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Results 
Participant Characteristics 
Means and standard deviations of Stroop performance and self-report measures at 
each of the three assessments are presented in Table 9. Analysis of the baseline (T1) data 
showed that patients were more variable in the incongruent condition of the slowest RT 
trials compared to controls, t(46) = -2.92, p < .01, d = 0.88. Patients tended to report more 
anxiety, t(46) = -2.13, p = .04, d = 0.64. Groups did not significantly differ in other 
baseline Stroop performance variables (i.e., accuracy on congruent and incongruent trials, 
mean RT, ISD scores), self-reported cognition (i.e., PAOFI and FACT-Cog 3), or 
symptoms of depression or fatigue. 
Stroop RT Task  
The percentage of RT trials excluded was small; T1 = 2.0%; T2 = 1.5%; T3 = 
1.4%. Groups showed similar changes from T1-T2 accuracy, mean reaction time, and 
ISD for both congruent and incongruent conditions (Table 10).3 There were no significant 
group by task condition interactions involving T1-T2 change scores. From T1 to T3, 
there were significant group effects in ISD change scores for both congruent and 
incongruent task conditions; patients did not improve as much as controls did at T3 
(Table 10).4 Analysis of change scores of the fastest and slowest RT trials revealed a 
relative decline in patients compared to controls on the slowest trials indexed by ISD and 
mean RT (congruent task condition only). T1-T3 change was otherwise similar between 
                                                3"Age predicted T2 test scores on congruent and incongruent IIV of the fastest trials (ps = .01). Change in 
depression symptoms predicted T2 scores on PAOFI Memory (p = .03), PAOFI Higher Level Cognition (p 
= .003), and FACT-Cog Total (p = .02). 4"Age predicted T3 scores on incongruent accuracy and congruent ISD of the slowest trials (ps = .02). 
Change in depression symptoms predicted T3 scores on: PAOFI Sensorimotor (p = .002), PAOFI Higher 
Level Cognition (p = .05), PAOFI Total (p = .02), and FACT-Cog Total (p < .001)."
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groups on accuracy and mean RT across all trials. There were no significant group by 
task condition interactions.5 
Self-Report Cognition 
Change scores from T1 to T2 on the PAOFI did not significantly differ between 
patients relative to controls (Tables 10 and 11). Patients reported significantly more 
cognitive symptoms at T3 than T1 on the PAOFI Sensorimotor subscale and total score, 
but did not significantly differ on the other PAOFI subscales. On the FACT-Cog 3, there 
were no significant group differences in change scores from T1 to T2 or T1 to T3. 
Analysis of clinically meaningful change on FACT-Cog 3 scores revealed no significant 
differences between patients and controls from T1 to T2 (44% vs. 29%, respectively, χ2 = 
.85, p = .36), or T1 to T3 (56% vs. 26%, respectively, χ2 = 3.81, p = .05). 
Intercorrelations Between Change in Stroop RT Task and Self-Reported Cognition 
 Changes in self-reported cognitive function from T1 to T2 were not significantly 
related to changes in objective Stroop performance measures in patients (rs ranged from -
.02 to .31) or controls (rs ranged from -.002 to .45). From T1 to T3, change in PAOFI 
language score was significantly positively correlated with ISD change scores in patients 
for congruent (r =.52) and incongruent conditions (r = .50; Table 12). Change scores on 
other PAOFI subscales and FACT-Cog 3 were not significantly correlated with change in 
variability on either congruent or incongruent Stroop conditions (rs ranged from -.001 to 
.45). In controls, there were no significant correlations between self-report cognitive 
symptoms and objective performance (rs ranged from -.01 to .50; Table 13).  
                                                
5 In order to test whether results are due to learning difficulties with button/color mapping, we performed 
data analyses on the final block of the Stroop task (i.e., last 96 trials) at baseline, which served as a proxy 
for successful acquisition of button/color mapping and effort by the end of the task. The pattern of results 
for the last 96 trials was identical to results based on all trials."
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Table 9. Means and Standard Deviations for Patient and Healthy Control Groups on Cognitive and Self-Report Measures 
 Time 1  Time 2  Time 3 
 
 
Variables  
Patients 
(n = 28) 
Control 
(n = 20)  
Patients 
(n = 18) 
Control 
(n = 17)  
Patients 
(n = 25) 
Control 
(n = 16) 
Accuracy, %         
   Congruent 99.3 (0.7) 98.9 (1.4)  99.5 (0.7) 98.7 (1.6)  98.9 (1.2) 98.1 (2.2) 
   Incongruent 97.7 (1.8) 96.8 (3.9)  97.0 (5.2) 97.7 (2.6)  98.3 (2.3) 97.3 (3.0) 
Mean RT, ms         
   Congruent 797.7 (164.7) 741.3 (116.3)  763.2 (164.9) 729.1 (120.0)  784.6 (179.0) 694.5 (93.9) 
   Incongruent 956.3 (220.6) 872.7 (157.2)  910.2 (232.2) 857.6 (152.3)  925.3 (231.8) 806.1 (123.7) 
Mean RT – fastest, ms         
   Congruent 571.3 (120.4) 530.7 (91.9)  549.8 (126.6) 521.0 (90.0)  553.8 (138.9) 500.8 (83.9) 
   Incongruent 574.6 (133.6) 531.4 (93.3)  553.7 (136.5) 518.9 (85.6)  555.3 (155.6) 504.2 (91.5) 
Mean RT – slowest, ms         
   Congruent 1238.9 (250.7) 1151.1 (185.1)  1191.0 (209.6) 1154.1 (204.9)  1238.4 (264.0) 1051.4 (139.7) 
   Incongruent 1319.9 (301.6) 1199.9 (196.4)  1268.8 (284.1) 1192.9 (218.9)  1300.0 (316.3) 1111.7 (153.3) 
ISD         
   Congruent 7.3 (1.8) 6.7 (1.3)  7.5 (1.1) 7.2 (1.9)  7.8 (1.8) 6.2 (1.2) 
   Incongruent 9.7 (2.4) 8.6 (1.6)  9.7 (2.0) 9.2 (1.9)  9.8 (2.5) 7.9 (1.5) 
ISD – fastest         
   Congruent 2.2 (0.9) 1.9 (0.5)  2.0 (0.7) 1.8 (0.5)  2.0 (0.8) 1.8 (0.5) 
   Incongruent 2.2 (0.9) 2.0 (0.7)  1.9 (0.8) 1.9 (0.6)  1.9 (0.7) 1.7 (0.4) 
ISD – slowest         
   Congruent 5.2 (1.5) 5.3 (1.5)  6.07 (2.0) 6.4 (1.4)  6.2 (1.9) 4.7 (0.8) 
   Incongruent 8.2 (1.8) 6.8 (1.4)  8.3 (1.9) 7.6 (1.3)  8.2 (1.7) 6.1 (1.2) 
   
 
75 
Note. Values in parentheses are standard deviations unless otherwise indicated. 
ChT = chemotherapy; FACT-Cog 3 = Functional Assessment of Cancer Therapy – Cognitive Function; FACIT = Functional Assessment of Chronic Illness 
Therapy Fatigue; HADS=Hospital Anxiety and Depression Scale; ISD = Intraindividual Standard Deviation; PAOFI = Patient’s Assessment of Own Functioning 
Inventory; RT = Reaction Time.
PAOFI Total 28.2 (15.3) 27.0 (15.9)  36.9 (24.7) 25.4 (18.0)  39.8 (21.8) 25.5 (18.9) 
   “High Complaints” n = 6 (21%) n = 3 (15%)  n = 6 (33%) n = 4 (24%)  n = 11 (44%) n = 11 (44%) 
PAOFI Subscales         
   Memory  12.7 (9.2) 9.7 (5.7)  15.1 (10.3) 9.5 (7.8)  15.9 (9.1) 10.0 (7.4) 
   Language 7.9 (4.6) 8.6 (6.3)  10.5 (6.8) 8.8 (5.6)  11.5 (7.1) 9.2 (7.5) 
   Sensorimotor 1.7 (2.0) 2.5 (3.0)  4.1 (4.8) 3.0 (3.0)  4.7 (4.9) 1.9 (1.9) 
   Higher Level 5.9 (5.3) 6.2 (6.1)  5.6 (6.0) 4.1 (6.0)  7.7 (6.1) 4.5 (5.7) 
FACT-Cog 3 Total 41.0 (27.4) 27.5 (18.9)  51.2 (30.7) 33.1 (24.6)  53.0 (29.9) 31.3 (26.0) 
HADS         
   Total  12.8 (7.8) 8.3 (7.0)  10.8 (6.9) 7.8 (7.7)  11.1 (7.4) 7.8 (6.4) 
   Depression 4.3 (4.0) 2.8 (3.3)  5.3 (3.8) 2.4 (3.8)  4.5 (3.3) 1.9 (1.9) 
      Normal n = 24 (86%) n = 17 (85%)  n = 12 (67%) n = 14 (82%)  n = 20 (80%) n = 16 (100%) 
      Mild n = 0 (0%) n = 2 (10%)  n = 5 (28%) n = 2 (12%)  n = 5 (20%) n = 0 (0%) 
      Moderate n = 3 (11%) n = 1 (5%)  n = 1 (5%) n = 1 (6%)  n = 0 (0%) n = 0 (0%) 
      Severe n = 1 (3%) n = 0 (0%)  n = 0 (0%) n = 0 (0%)  n = 0 (0%) n = 0 (0%) 
  Anxiety 8.4 (5.0) 5.6 (4.0)  5.6 (3.5) 5.4 (4.7)  5.8 (4.8) 5.8 (4.8) 
      Normal n = 12 (43%) n = 16 (80%)  n = 12 (67%) n = 11 (65%)  n = 13 (52%) n = 11 (69%) 
      Mild n = 6 (21%) n = 2 (10%)  n = 4 (22%) n = 4 (23%)  n = 5 (20%) n = 3 (19%) 
      Moderate n = 7 (25%) n = 1 (5%)  n = 2 (11%) n = 1 (6%)  n = 7 (28%) n = 1 (6%) 
      Severe n = 3 (11%) n = 1 (5%)  n = 0 (0%) n = 1 (6%)  n = 0 (0%) n = 1 (6%) 
FACIT - Fatigue 13.1 (10.0) 9.0 (9.3)  23.0 (12.6) 10.6 (12.7)  16.2 (8.4) 9.6 (8.6) 
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Table 10. One-Way Analysis of Variance (ANOVA) of SRB Scores on Cognitive and Self-Report Measures By Group 
 Time 1 – Time 2 Time 1 – Time 3 
 
Variables 
Patients 
Mean (SD) 
Controls 
Mean (SD) t p d  
Patients 
Mean (SD) 
Control 
Mean (SD) t p d 
Accuracy, %            
   Congruent 0.31 (0.73) -0.00 (0.97) -1.07 .29 .37  -0.05 (0.78) -0.00 (0.97) .17 .86 .05 
   Incongruent -0.39 (2.10) 0.00 (0.97) .72 .48 .25  0.17 (1.32) -0.00 (0.93) -.46 .65 .15 
 
Mean RT, ms 
           
   Congruent 0.17 (1.40) -0.00 (0.97) -.42 .68 .15  0.68 (1.26) 0.00 (0.97) -1.83 .08 .59 
   Incongruent 0.22 (1.44) -0.00 (0.97) -.53 .60 .18  0.55 (1.02) 0.00 (0.97) -1.73 .09 .55 
 
Mean RT – fastest, ms 
           
   Congruent -0.09 (1.96) -0.00 (0.97) .17 .87 .06  0.32 (1.51) -0.00 (0.97) -.76 .45 .24 
   Incongruent 0.08 (1.68) 0.00 (0.97) .17 .87 .06  0.05 (1.44) -0.00 (0.97) -.11 .91 .04 
 
Mean RT – slowest, ms 
           
   Congruent -0.03 (0.91) 0.00 (0.97) .08 .93 .03  1.20 (1.27) -0.00 (0.97) -3.22 .003 1.03 
   Incongruent 0.09 (1.58) 0.00 (0.97) -.21 .84 .07  0.86 (1.22) -0.00 (0.97) -2.39 .02 .77 
 
ISD 
           
   Congruent 0.14 (1.07) 0.00 (0.97) -.41 .69 .14  1.14 (1.11) 0.00 (0.97) -3.39 .002 1.09 
   Incongruent -0.08 (1.51) 0.00 (0.97) .19 .85 .07  0.92 (1.23) -0.00 (0.97) -2.55 .01 .82 
 
ISD – fastest 
           
   Congruent 0.54 (1.14) 0.00 (0.94) -1.52 .14 .53  -0.07 (0.96) 0.00 (0.96) 0.23 .82 .07 
   Incongruent 0.09 (1.35) 0.00 (0.94) -.23 .82 .08  0.22 (1.81) 0.00 (0.97) -0.45 .66 .14 
 
ISD – slowest 
           
   Congruent -0.18 (1.38) 0.00 (0.97) .45 .65 .16  1.97 (2.17) -0.00 (0.93) -3.98 .0003 1.34 
   Incongruent 0.52 (1.34) 0.00 (0.97) -.13 .90 .05  1.53 (1.42) -0.00 (0.93) -3.78 .0005 1.21 
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Note. FACT-Cog = Functional Assessment of Cancer Therapy – Cognitive Function; ISD = Intraindividual Standard Deviation; PAOFI = Patient’s Assessment 
of Own Functioning Inventory; RT = Reaction Time; SRB = Standardized Regression-Based
PAOFI            
   Total 1.11 (1.88) 0.00 (0.97) -2.12 .05 .90  0.98 (1.03) -0.00 (0.93) -3.03 .004 .97 
   Memory 0.28 (1.40) -0.00 (0.94) -.67 .50 .23  0.75 (1.14) -0.00 (0.97) -2.14 .04 .69 
   Language 0.89 (1.53) -0.00 (0.97) -2.02 .05 .70  0.87 (1.14) 0.00 (0.97) -2.49 .02 .82 
   Sensorimotor 0.46 (1.66) 0.00 (0.97) -.96 .35 .33  2.51 (3.32) 0.00 (0.93) -3.44 .002 1.10 
   Higher Level 0.92 (2.04) -0.00 (0.94) -1.64 .04 .72  0.73 (1.11) -0.00 (0.93) -2.16 .04 .69 
 
FACT-Cog 3 
           
   Total 0.30 (2.12) 0.00 (0.94) -.52 .61 .22  0.14 (1.59) 0.00 (0.93) -.36 .72 .12 
   
 
78 
Table 11. Number of Patients and Controls with Significant Decline Based on SRB Change Scores 
Number (%) Time 1 – Time 2a  Time 1 – Time 3b 
Variables Patients Controls 
p -value 
(odds ratio) 
 
Patients Controls 
p -value 
(odds ratio) 
Accuracy        
   Congruent 0/18 (6%) 0/17 (0%) 1.00 (UND)  0/25 (0%) 0/16 (0%) 1.00 (UND) 
   Incongruent 0/18 (6%) 0/17 (6%) 1.00 (UND)  1/25 (4%) 1/16 (6%) .85 (.63) 
 
Mean RT    
    
   Congruent 2/18 (11%) 0/17 (0%) .26 (UND)  5/25 (20%) 1/16 (6%) .23 (3.75) 
   Incongruent 3/18 (17%) 1/17 (6%) .32 (3.20)   2/25 (8%) 0/16 (0%) .37 (UND) 
 
ISD    
    
   Congruent 1/18 (6%) 0/17 (0%) .51 (UND)  6/25 (24%) 1/16 (6%) .15 (4.74) 
   Incongruent 1/18 (6%) 1/17 (6%) .77 (0.94)  5/25 (20%) 1/16 (6%) .23 (3.75) 
 
PAOFI    
    
   Total 4/16 (25%) 0/17 (0%) .04 (UND)  2/23 (9%) 1/16 (6%) .64 (1.43) 
   Memory 2/16 (13%) 1/17 (6%) .48 (2.29)  5/23 (22%) 1/16 (6%) .20 (4.2) 
   Language 4/16 (25%) 0/17 (0%) .04 (UND)  4/23 (17%) 1/16 (6%) .30 (3.16) 
   Sensorimotor 1/16 (6%) 1/17 (6%) .77 (1.07)  11/23 (48%) 0/16 (0%) <.001 (UND) 
   Higher Level 5/16 (31%) 0/17 (0%) .02 (UND)  4/23 (17%) 1/16 (6%) .30 (3.16) 
 
FACT-Cog 3    
    
   Total 3/17 (18%) 0/17 (0%) . 11 (UND)  3/24 (13%) 1/16 (6%) .47 (2.14) 
Note. a n = 16 on PAOFI and n = 17 on FACT-Cog 3 due to incompletion of these measures. 
b n = 23 on PAOFI and n = 24 on FACT-Cog 3 due to incompletion of these measures. 
FACT-Cog = Functional Assessment of Cancer Therapy – Cognitive Function; ISD = Intraindividual Standard Deviation; PAOFI = Patient’s Assessment of Own 
Functioning Inventory; RT = Reaction Time; SRB = Standardized Regression Based 
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Table 12. Pearson Correlations of Cognitive and Self-Report Change between T1-T3 for Patients (n = 25) 
Note. p-values in parentheses; FACT – Cog =Functional Assessment of Cancer Treatment – Cognitive Function; ISD = Individual Standard Deviation; PAOFI = 
Patient’s Assessment of Own Functioning Inventory; RT = Reaction Time. 
 Accuracy 
Congruent 
Accuracy 
Incongruent 
Mean RT 
Congruent 
Mean RT 
Incongruent 
ISD 
Congruent 
ISD 
Incongruent 
PAOFI 
Total 
PAOFI 
Memory 
PAOFI 
Language 
PAOFI 
Sensori
-motor 
PAOFI 
Higher-
Order 
FACT-
Cog 3 
Total 
Accuracy 
Congruent 
1.00 -           
Accuracy  
Incongruent 
0.55 
(.004) 
1.00           
Mean RT 
Congruent 
0.22 
(0.29) 
-0.09 
(.65) 
1.00          
Mean RT 
Incongruent 
0.23 
(.27) 
-0.04 
(.85) 
0.86 
(<.001) 
1.00         
ISD 
Congruent 
0.09 
(.67) 
-0.25 
(.23) 
0.45 
(.02) 
0.42 
(.04) 
1.00        
ISD 
Incongruent 
-0.17 
(.41) 
-0.55 
(.004) 
0.27 
(.19) 
0.41 
(.04) 
0.73 
(<.001) 
1.00       
PAOFI  
Total 
-0.08 
(.73) 
-0.006 
(.98) 
0.04 
(.85) 
0.17 
(.44) 
0.44 
(.04) 
0.42 
(.05) 
1.00      
PAOFI 
Memory 
0.06 
(.79) 
-0.10 
(.66) 
0.01 
(.98) 
0.20 
(.35) 
0.36 
(.09) 
0.45 
(.03) 
0.82 
(<.001) 
1.00     
PAOFI 
Language 
-0.26 
(.24) 
-0.09 
(.68) 
-0.001 
(.99) 
0.11 
(.62) 
0.52 
(.01) 
0.50  
(.01) 
0.79 
(<.001) 
0.52 
(.01) 
1.00    
PAOFI 
Sensorimotor 
0.18 
(.40) 
-0.06 
(.79) 
0.36 
(.09) 
0.32 
(.13) 
0.40 
(.06) 
0.43 
(.04) 
0.52 
(<.001) 
0.54 
(<.001) 
0.25 
(.26) 
1.00   
PAOFI 
Higher-Order 
-0.13 
(.55) 
0.18 
(.41) 
-0.02 
(.94) 
-0.05 
(.83) 
0.09 
(.67) 
-0.07 
(.74) 
0.64 
(<.001) 
0.28 
(.20) 
0.41 
(.06) 
0.12 
(.59) 
1.00  
FACT-Cog 3 
Total 
-0.02  
(.91) 
-0.25  
(.23) 
-0.08  
(.72) 
0.26  
(.23) 
0.19  
(.37) 
0.31  
(.14) 
0.70 
(<.001) 
0.64 
(.001) 
0.41 
(.06) 
0.48 
(.02) 
0.48 
(.02) 
1.00 
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Table 13. Pearson Correlations of Cognitive and Self-Report Change between T1-T3 for Healthy Controls (n = 16) 
Note. p-values in parentheses; FACT – Cog =Functional Assessment of Cancer Treatment – Cognitive Function; ISD = Individual Standard Deviation; PAOFI = 
Patient’s Assessment of Own Functioning Inventory; RT = Reaction Time. 
 Accuracy 
Congruent 
Accuracy 
Incongruent 
Mean RT 
Congruent 
Mean RT 
Incongruent 
ISD 
Congruent 
ISD 
Incongruent 
PAOFI 
Total 
PAOFI 
Memory 
PAOFI 
Language 
PAOFI 
Sensori
-motor 
PAOFI 
Higher-
Order 
FACT-
Cog 3 
Total 
Accuracy 
Congruent 
1.00 -           
Accuracy  
Incongruent 
0.06 
(.82) 
1.00           
Mean RT 
Congruent 
0.20 
(0.45) 
0.08 
(.77) 
1.00          
Mean RT 
Incongruent 
0.25 
(.35) 
0.27 
(.32) 
0.88 
(<.001) 
1.00         
ISD 
Congruent 
0.28 
(.29) 
0.38 
(.14) 
0.56 
(.02) 
0.63 
(.008) 
1.00        
ISD 
Incongruent 
0.18 
(.51) 
0.47 
(.06) 
0.36 
(.18) 
0.66 
(.006) 
0.69 
(.003) 
1.00       
PAOFI  
Total 
-0.15 
(.58) 
-0.08 
(.76) 
0.01 
(.96) 
0.13 
(.64) 
-0.15 
(.59) 
0.11 
(.68) 
1.00      
PAOFI 
Memory 
-0.06 
(.82) 
-0.01 
(.96) 
0.02 
(.93) 
0.17 
(.52) 
-0.12 
(.65) 
0.18 
(.50) 
0.97 
(<.001) 
1.00     
PAOFI 
Language 
-0.06 
(.82) 
-0.06 
(.81) 
0.01 
(.96) 
0.12 
(.66) 
-0.20 
(.47) 
0.04  
(.88) 
0.90 
(<.001) 
0.83 
(<.001) 
1.00    
PAOFI 
Sensorimotor 
0.03 
(.89) 
-0.11 
(.68) 
0.50 
(.05) 
0.39 
(.14) 
0.18 
(.51) 
0.20 
(.45) 
0.37 
(.16) 
0.34 
(.19) 
0.29 
(.27) 
1.00   
PAOFI 
Higher-Order 
-0.37 
(.16) 
-0.13 
(.63) 
-0.25 
(.36) 
-0.14 
(.60) 
-0.18 
(.49) 
-0.02 
(.95) 
0.80 
(<.001) 
0.74 
(.001) 
0.59 
(.02) 
-0.06 
(.82) 
1.00  
FACT-Cog 3 
Total 
-0.22  
(.41) 
-0.22  
(.41) 
-0.08  
(.76) 
0.005  
(.99) 
-0.40  
(.12) 
-0.23  
(.39) 
0.75 
(<.001) 
0.68 
(.003) 
0.74 
(<.001) 
0.19 
(.48) 
0.64 
(.002) 
1.00 
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Discussion 
The main results of the present study indicate that, at the third assessment 
(occurring 9 months postchemotherapy), women treated for breast cancer have greater 
variability in Stroop RT relative to healthy controls, which is evidence of cognitive 
dysfunction. This finding is consistent with previous research reporting a decreased 
ability to benefit from practice in women treated for breast cancer (Collins et al., 2014; 
Stewart et al., 2008) and supports a multifaceted causation of cancer-related cognitive 
change, which includes the influences of cancer itself, surgery/anesthesia, hormone 
therapy, and chemotherapy. No significant group differences were found in change from 
baseline to T2, after chemotherapy. The analysis also showed IIV to be more sensitive 
than mean RT for capturing differences in change across all trials of the Stroop task. 
Congruent Stroop trials are affected by fundamental brain processes (e.g., 
perception and sensorimotor speed), whereas incongruent trials additionally require 
higher order cognition (e.g., inhibitory control). Given the subtle nature of cancer-related 
cognitive deficits, we might expect a greater group difference in the incongruent 
conditions, as we previously found in women before they had received surgery or 
chemotherapy (Chapter 3). However, present results show that patients did not have 
disproportionate difficulty on the more demanding task condition following treatment. 
Our findings of increased variability among patients in the slowest RT trials suggest a 
reduced ability to stay consistently focused on the specific goals of the task, which may 
then manifest in more frequent lapses in attention and increased variability (Bunce et al., 
1993; West et al., 2002). A similar pattern of increased variability in the slow end of the 
RT distribution has been seen in both normative and pathological aging (Duchek et al., 
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2009; Hultsch et al., 2002). This common mechanism of change in variability supports 
the hypothesis that biological processes underlying aging and cancer-related factors (e.g., 
impact of disease and treatment) are linked and that cancer treatments may accelerate the 
aging process (Ahles, Root, & Ryan, 2012; Maccormick, 2006) 
Change scores on PAOFI Total from T1 to T3 differed between groups due to 
increased reporting of cognitive symptoms among the patients. A significant proportion 
of patients also reported increased sensorimotor problems from T1 to T3, which may be 
related to chemotherapy-induced peripheral neuropathy that could potentially interfere 
with the manual responses required on the RT task. However, women with breast cancer 
did not make significantly more errors nor were they significantly slower than healthy 
controls, which would be expected if they experienced difficulty using the response 
keypad. 
Increased symptoms on the PAOFI Language subscale from T1 to T3 were 
significantly related to increased IIV in the same period. This association might be related 
to initiation of hormone therapy in the majority of women with breast cancer by T3, 
given the demonstrated positive relationship between estradiol levels and verbal fluency 
and verbal memory (Kampen & Sherwin, 1994; Maki, Rich, & Rosenbaum, 2002). There 
were no significant effects showing associations on PAOFI total and other subscales and 
variability.  
A potential limitation of the study is fluctuation of the number of participants 
across the assessment points. To address this, we analyzed the data using only 
participants who completed all three assessments and found the same pattern of results, 
namely a reduced ability to benefit from repeated testing among patients from T1 to T3. 
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Due to small sample size, we were unable to examine performance differences between 
women who did or did not receive hormone therapy at T3. Another limitation is the 
inclusion of only one measure of IIV. Although we examined performance at different 
levels of task difficulty (e.g., congruent and incongruent conditions), the inclusion of 
tasks assessing other domains (e.g., semantic or lexical decision) would provide greater 
insights into the pattern of cancer-related cognitive dysfunction. 
Strengths of this study include its prospective longitudinal study design, which 
permits comparisons to baseline performance before both surgery and chemotherapy, and 
the high participant retention rate (88-96%). A closely matched healthy control group 
allowed for full estimate of practice effects. We accounted for the potential confounding 
effects of age, group differences in mean RT, and practice effects in IIV. Finally, groups 
were not significantly different on accuracy across assessment points, which suggest that 
the control group did not demonstrate a speed/accuracy trade-off that could extraneously 
result in a faster performance. 
In conclusion, healthy individuals show performance gains from repeated 
assessments, whereas women with breast cancer treated with neoadjuvant chemotherapy 
did not demonstrate expected benefits of practice. IIV is a sensitive and meaningful 
indicator of cognitive performance, which may be particularly relevant for women with 
breast cancer because of the subtle effects of cancer treatment on cognitive function.  
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Chapter 5: General Discussion 
 The purpose of the dissertation was to examine executive functioning in women 
with breast cancer using IIV measures of cognitive performance. The key findings from 
the studies are summarized below, followed by a discussion of theoretical implications of 
the results. Finally, limitations of the present studies and future avenues for research 
examining IIV in women with breast cancer are suggested. 
Summary of Studies 
The systematic review (Chapter 2) provided an overview of performance on 
neuropsychological and experimental tests of four subcomponents of executive 
functioning in women treated with chemotherapy. Inhibition seemed to be relatively 
unaffected in breast cancer survivors, whereas the findings were largely inconsistent for 
tasks assessing set-shifting, working memory, or planning/decision making. The 
substantial heterogeneity in study methods (e.g., clinical samples, study design, statistical 
procedures) used to define impairment and assess group differences contributed to the 
mixed results. Recommendations for future research included careful operationalization 
of executive functioning and selection of appropriate tasks as well as alternative methods 
to examine performance. In particular, the inclusion of tasks of varying complexity and 
measures of within-person variability were hypothesized to yield unique information 
about cognitive functioning in women diagnosed and treated for breast cancer.  
The remainder of this dissertation was a report of IIV in Stroop RT performance 
among women diagnosed with breast cancer compared to healthy controls at baseline 
(Chapter 3) and follow-up after neoadjuvant chemotherapy and other adjuvant treatments 
(e.g., surgery, hormone therapy; Chapter 4). Assessment before and after neoadjuvant 
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chemotherapy provided an opportunity to examine the effects of chemotherapy without 
the confounding effects of surgery and anesthesia. A Stroop RT task that included two 
conditions of varying complexity was used at all assessments. Women diagnosed with 
breast cancer were more variable prior to receiving neoadjuvant chemotherapy (i.e., at 
baseline) compared to healthy controls only on the more difficult, incongruent condition 
of the task.  
Change in overall IIV from baseline to 1-month postchemotherapy did not differ 
between breast cancer patients and controls. However, change from baseline to 9-months 
postchemotherapy revealed a relative deficit in patients, as they did not improve on either 
task condition as much as healthy controls did. Self-reported cognitive symptoms also 
increased from baseline to 9-months postchemotherapy in patients relative to controls. In 
patients, there was a significant positive correlation between change in self-reported 
language difficulties and change in variability at 9-months postchemotherapy. However 
in controls, there were no significant correlations between change in self-reported 
symptoms and change in Stroop performance. Both at baseline and across assessments, 
IIV was a more sensitive measure of group differences than was mean RT.  
These results suggest that there are cognitive deficits related to breast cancer itself 
and associated treatments (e.g., surgery/anesthesia, chemotherapy, hormone therapy). 
Overall, findings contribute to the current understanding of the behavioural relationship 
between IIV and cognitive functioning in women with breast cancer. Findings also add to 
the IIV literature suggesting that variability is a sensitive measure that is able to detect 
subtle differences and changes in women with breast cancer (Bernstein et al., 2014). 
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Longitudinal Change in IIV in Women with Breast Cancer 
 A prospective longitudinal design is recommended to document performance 
trends across time and to account for baseline level of functioning (Wefel, Vardy, Ahles, 
& Schagen, 2011). The data reported here add to the accumulating literature that 
demonstrates pretreatment cognitive deficits in breast cancer patients relative to 
comparison groups. The deficit was present only in the slowest trials of the RT 
distribution from the Stroop task and when indexed by IIV, which is hypothesized to be a 
more sensitive measure of neural integrity than mean RT (Lövdén et al., 2007). It is 
unclear from the data whether increased pretreatment variability in women diagnosed 
with breast cancer is due to the cancer itself or other unidentified factors such as, 
posttraumatic stress. However, pretreatment variability was not significantly correlated 
with age, education, days since diagnosis, depression, anxiety, fatigue, or self-reported 
cognition.  
 In contrast to many longitudinal studies that show cognitive impairment in 
women during (Collins et al., 2013b) and immediately after (Debess et al., 2010; 
Hermelink et al., 2007: Vearncombe et al., 2009) chemotherapy, the present data did not 
reveal any significant effects of neoadjuvant chemotherapy 1 month posttreatment. At 9 
months postchemotherapy, however, women with breast cancer did not show decreased 
variability from baseline to the extent that healthy women did. By this assessment point, 
women with breast cancer had received additional treatments (e.g., surgery/anesthesia, 
hormone therapy) that could have negative effects on cognitive functioning. The results 
should be considered tentative due to the small sample size. It will be important for future 
studies to follow patients longer term, given cross-sectional findings of cognitive 
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impairment 5 to 9 years postchemotherapy on functional imaging studies (de Ruiter et al., 
2011; Kesler et al., 2011) and 10 to 20 years postchemotherapy on neuropsychological 
testing (Koppelmans et al., 2012; Nguyen et al., 2013). 
Relationship between Self-Reported Cognition and Objective Performance 
 Previous studies show that self-reported cognitive symptoms do not correlate with 
performance on objective neuropsychological tests (Pullens et al., 2010), whereas 
symptoms do correlate with measures of depression, anxiety, and posttraumatic stress 
associated with the breast cancer diagnosis (Hermelink et al., 2015; Shilling & Jenkins, 
2007; van Dam et al., 1998). The dissociation between self-report and objective cognition 
has been accounted for by various explanations including that testing conducted in a 
structured environment lacks the ecological validity of daily functioning (Bender et al., 
2008; Downie, Mar Fan, Houédé-Tchen, Yi, & Tannock, 2006; Shilling & Jenkins, 2007) 
or patient’s ability to compensate for subtle neural dysfunction that is evident in fMRI 
studies but not on neuropsychological test performance (Ferguson et al., 2007; McDonald 
et al., 2012; Silverman et al., 2006). It is likely that both types of assessment are 
important for characterizing cognitive impairment after breast cancer treatment, as they 
may reflect different but overlapping constructs. 
 One of the aims of this dissertation was to investigate whether IIV, hypothesized 
as a unique and sensitive measure to detect cognitive impairment related to breast cancer 
and treatment, is related to self-reported differences between patients and healthy 
controls. Consistent with previous studies, we found no significant association between 
change in self-reported cognition and change in objective performance from baseline to 1 
month postchemotherapy. In the baseline to 9-month postchemotherapy period, change in 
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self-reported language symptoms was positively correlated with change in variability 
among patients but not healthy individuals. The timeframe of reference may be 
particularly important in studying the relationship between self-reported cognition and 
objective performance. For example, Collins, Paquet, Dominelli, White, and MacKenzie, 
(2015) proposed that participants likely rate their current level of functioning in relation 
to their baseline level in self-reports, which automatically references a change in 
function. However, most objective scores are typically based on a single assessment 
point. Recently, a study found that change in psychomotor speed was associated with 
higher language complaints on the PAOFI 6 months after starting hormone treatment 
(Ganz et al., 2014). The present findings of associations between subjective appraisals 
and objective performance using change scores support the hypothesis that timeframe of 
reference may be an important methodological consideration.  
Further Considerations of IIV 
 Results from this dissertation suggest that IIV is a sensitive indicator of cognitive 
functioning that provides information that is unique from mean level performance (i.e., 
accuracy and mean RT). At baseline, breast cancer patients were shown to have difficulty 
on the more complex condition (incongruent trials) in the slowest trials only when 
measured using variability and not by accuracy or mean RT. In terms of baseline to 9-
month postchemotherapy change, women with breast cancer showed relative increases in 
both congruent and incongruent IIV across the entire RT distribution compared to healthy 
individuals, whereas significant RT differences were seen only in the slowest trials of RT 
and not across the entire distribution. Thus, IIV captured information about cognitive 
functioning in women with breast cancer that would have been unobserved if only mean 
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performance level was examined. This underscores the utility of including measures of 
variability when evaluating cognition in women with breast cancer. 
 Another consideration for IIV is the influence of task complexity on performance 
variability. Studies have shown that increased IIV is associated with tasks that involve 
greater cognitive demands (Hultsch et al., 2000; West et al., 2002). Consistent with these 
findings, women newly diagnosed with breast cancer demonstrated increased IIV on the 
Stroop condition that required greater attentional control compared to the condition of 
simple attention. The Stroop task involved 384 trials and required approximately 12 to 15 
minutes to complete. Thus, in this regard, IIV on this task may also be related to 
sustained attention. However, examination of the last block of trials (i.e., last 96 trials) 
yielded similar results to that of the entire 384 trials, which suggested that observed 
group differences were not due to poor sustained attention or increased fatigue over the 
course of the test. As discussed in Chapter 3, these findings suggest that the elevated IIV 
in patients might reflect fluctuations in executive control or lapses in attention. In both 
interpretations, the concept of IIV reflects frontally mediated processes which include 
maintaining attention and executive control. 
 After neoadjuvant chemotherapy, women with breast cancer relative to healthy 
individuals showed increased IIV in congruent and incongruent Stroop task conditions 
across the entire RT distribution and specifically in the slowest trials. This finding 
suggests that variability represents a general characteristic of overall performance and not 
just for the most difficult condition, which emphasizes the effect of chemotherapy 
beyond pretreatment differences in performance. The results are consistent with other 
studies that show IIV is a general characteristic of performance in individuals with mild 
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cognitive impairment (Christensen et al., 2005; Dixon et al., 2007; Duchek et al., 2009). 
The increase in IIV is also consistent within an attentional control framework on a simple 
and complex task. Specifically, the major goal of the cognitive system is to flexibly 
adjust itself to current task demands and stay tuned to these demands across time. As 
attentional control systems becomes compromised due to the negative effects of breast 
cancer treatment, these systems are no longer consistently tuned across time to the 
specific goals of the task that are both simple and more complex in nature.  
Limitations and Directions for Future Research 
Whereas there are several strengths of the studies comprising this dissertation, 
including the prospective longitudinal study design and operationalization of IIV, there 
are some limitations that warrant further consideration. One limitation is that not every 
person was assessed at every time point, which reduced power to detect differences 
between women with breast cancer and healthy controls in the baseline to 1-month 
postchemotherapy assessment period. Besides the issue of small sample size, participants 
were relatively homogenous. Female participants were predominantly middle-aged and 
well-educated, which limits generalizability of the findings to a broader breast cancer 
population. Another limitation is the increased possibility of Type I error due to the 
numerous statistical comparisons that are reported. To reduce the likelihood of Type I 
error, a more conservative p  < .01 was used to correct for multiple comparisons. These 
limitations present opportunities for future research to replicate and extend the findings of 
this dissertation in a larger and more diverse sample. 
Further research is needed to examine IIV derived from tasks assessing other 
cognitive domains to determine whether executive functioning is selectively impaired in 
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women or if the pattern of deficits is global and nonspecific. In this dissertation, IIV was 
conceptualized as an indicator of vulnerability and assessed with a task requiring 
attentional control. As described in Chapter 1, IIV has also been hypothesized to be 
adaptive under certain task conditions (Allaire & Marsiske, 2005; Garrett, MacDonald, & 
Craik, 2012). In contrast to most RT tasks that are strategy-constrained, complex 
cognitive tasks that incorporate learning and multiple response strategies would likely 
yield an adaptive index of variability (Allaire & Marsiske, 2005). Future studies should 
evaluate IIV as an indicator of adaptability or resiliency in women with breast cancer 
given that many longitudinal studies show improvement in cognitive functioning 
approximately one year after chemotherapy (Collins et al., 2009; Jansen et al., 2011). 
The present results established group differences in IIV between women with 
breast cancer and healthy controls at baseline and change after neoadjuvant 
chemotherapy. It will be important to extend the findings by examining possible links 
between increases in IIV, performance on neuropsychological tests, and neural correlates. 
If increased IIV is a behavioural marker of reduced neural integrity, then we may expect 
a corresponding decrease in performance on cognitive tasks, particularly more complex 
ones. Comparison of IIV measures with standardized neuropsychological tests might 
assist with understanding how IIV can complement standardized testing, which may have 
clinical implications for assessments of women with breast cancer and contribute toward 
defining diagnostic criteria for “chemo brain,” which still do not exist. In addition, 
understanding the neural underpinnings of IIV in breast cancer patients can inform the 
mechanisms underlying increased variability and lead to better understanding of breast 
cancer-related cognitive dysfunction. 
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As in the cognitive aging literature, IIV may be a prospective marker of important 
outcomes in women with breast cancer. Given the findings of increased pretreatment IIV 
in women with breast cancer, it would be interesting to determine whether IIV predicts 
cognitive decline after chemotherapy and other adjuvant treatment. Early identification of 
women at risk for treatment-related cognitive impairment is important for developing 
potential prevention or treatment options (e.g., cognitive intervention or rehabilitation 
programs) and improving long-term quality of life. This focus is particularly important in 
the context of increased breast cancer survivorship; however, substantial research is 
needed to bridge the gap between cognitive literature and clinical practice. 
Conclusions 
 Women diagnosed with breast cancer exhibit increased IIV compared to healthy 
controls before and after chemotherapy on tasks of varying demands on attentional 
resources. The studies presented here further our understanding of differences and 
changes in cognitive performance related to breast cancer and its treatments. 
Furthermore, findings demonstrate that IIV is an important characteristic that describes 
cognitive functioning in the breast cancer population. IIV holds promise for improving 
our understanding of complex processes and is a theoretically important aspect of 
functioning not captured by central tendency. 
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Appendix A: Stroop Reaction Time Task Instructions 
Colour-To-Key Mapping Acquisition Trials 
In this task you will press 1 of 4 buttons to indicate the color of the letters or word that 
appears on the screen. The colors are red, blue, green, and yellow. Before beginning the 
test trials you will have a chance to practice the color-to-button mapping so that you 
know which button corresponds to which color. 
                        
I [Research Assistant] will show you how to position your hands over the response box 
buttons.   
 
I [Research Assistant] will also review which button corresponds to red, blue, green, and 
yellow. 
  
Please take a few minutes right now to get familiar with the button/color mapping. 
  
After you feel you know them pretty well, you should begin practice trials.  I [Resarch 
Assistant] will go over these with you and give you feedback. 
  
<Colour-To-Key Mapping Acquisition Trials begins.> 
 
Practice Trials 
 
Now you will practice the Stroop task. For each trial, press the key to indicate the color 
that the word appears in. Be careful not to respond to the word that is presented. 
  
<Practice Trials begins.> 
  
Test Trials 
  
Now you will perform 4 blocks of 96 trials. Remember to always respond to the color of 
the font.  Do not ‘read’ what the word says; indicate the color that the word appears in. 
Respond as quickly as you can without making mistakes.     
            Indicate the color that the word appears in.  
            Respond as quickly as you can without making mistakes. 
  
<Test Block 1 begins.> 
  
Take a break. Press any button to continue to the next block of trials. 
  
<Test Block 2-4 begins.> 
  
This is the end of the task. Thank you for your participation. 
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Appendix B: Hospital Anxiety and Depression Scale (HADS) 
Instructions: Read each item and place a tick in the box opposite the reply that comes closet to 
how you have been feeling in the past week. Don’t take too long over your replies; your 
immediate reaction to each item will probably be more accurate than a long though-out response. 
Tick only one box in each section.
 
I feel tense or wound up: 
! Most of the time 
! A lot of the time 
! Time to time 
! Not at all 
 
I still enjoy the things I used to enjoy: 
! Definitely as much 
! Not quite so much 
! Only a little 
! Hardly at all 
 
I get a sort of frightened feeling as if 
something awful is about to happen: 
! Very definitely and quite badly 
! Yes, but not too badly 
! A little, but it doesn’t worry me 
! Not at all 
 
I can laugh and see the funny side of things: 
! As much as I always could 
! Not quite as much now 
! Definitely not so much now 
! Not at all 
 
Worrying thoughts go through my mind: 
! A great deal of the time 
! A lot of the time 
! From time to time but not too often 
! Only occasionally 
 
I feel cheerful: 
! Not at all 
! Not often 
! Sometimes 
! Most of the time 
 
I can sit at ease and feel relaxed 
! Definitely 
! Usually  
! Not often 
! Not at all 
 
I feel as if I am slowed down: 
! Nearly all the time 
! Very often 
! Sometimes 
! Not at all 
 
I get a sort of a frightened feeling like 
butterflies in the stomach: 
! Not at all 
! Occasionally 
! Quite often 
! Very often 
 
I have lost interest in my appearance: 
! Definitely 
! I don’t take so much care as I should 
! I may not take quite as much care 
! I take just as much care as ever 
 
I feel restless as if I have to be on the move: 
! Very much indeed 
! Quite a lot 
! Not very much 
! Not at all 
 
I look forward with enjoyment to things: 
! As much as I ever did 
! Rather less than I used to 
! Definitely Less than I used to 
! Hardly at all 
 
I get sudden feelings of panic: 
! Very often indeed 
! Quite often 
! Not very often 
! Not at all 
 
I can enjoy a good book or radio or TV 
program: 
! Often 
! Sometimes 
! Not often 
! Very seldom
!  
   
 
122 
Appendix C: FACIT-F 
Instructions: By circling one number per line, please indicate how true each statement 
has been for you during the past 7 days. 
 
 Not 
at all 
A little 
bit 
Some-
what 
Quite 
a bit 
Very 
much 
I feel fatigued 0 1 2 3 4 
I feel weak all over 0 1 2 3 4 
I feel listless (“washed out”) 0 1 2 3 4 
I feel tired 0 1 2 3 4 
I have trouble starting things because I am 
tired 
0 1 2 3 4 
I have trouble finishing things because I am 
tired 
0 1 2 3 4 
I have energy 0 1 2 3 4 
I am able to do my usual activities 0 1 2 3 4 
I need to sleep during the day 0 1 2 3 4 
I am too tired to eat 0 1 2 3 4 
I need help doing my usual activities 0 1 2 3 4 
I am frustrated by being too tired to do the 
things I want to do 
0 1 2 3 4 
I have to limit my social activity because I am 
tired 
0 1 2 3 4 
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Appendix D: FACT-Cognitive Function Version 3 
Instructions: Below is a list of statements that other people with your condition 
have said are important. Please circle or mark one number per line to indicate your 
response as it applies to the past 7 days. 
 
 
Perceived Cognitive Impairments 
Never About 
once a 
week 
Two to 
times a 
week 
Nearly 
every 
day 
Several 
times a 
day 
I have had trouble forming thoughts 0 1 2 3 4 
My thinking has been slow 0 1 2 3 4 
I have had trouble concentrating 0 1 2 3 4 
I have had trouble finding my way to a 
familiar place 
 
0 1 2 3 4 
I have had trouble remembering where I 
put things, like my keys or my wallet 
 
0 1 2 3 4 
I have had trouble remembering new 
information, like phone numbers or simple 
instructions 
 
0 1 2 3 4 
I have had trouble recalling the name of an 
object while talking to someone 
 
0 1 2 3 4 
I have had trouble finding the right 
word(s) to express myself 
 
0 1 2 3 4 
I have used the wrong word when I 
referred to an object 
 
0 1 2 3 4 
I have had trouble saying what I mean in 
conversations with others 
 
0 1 2 3 4 
I have walked into a room and forgotten 
what I meant to get or do there 
 
0 1 2 3 4 
I have had to work really hard to pay 
attention or I would make a mistake 
 
0 1 2 3 4 
I have forgotten names of people soon 
after being introduced 
 
0 1 2 3 4 
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My reactions in everyday situations have 
been slow 
 
0 1 2 3 4 
I have had to work harder than usual to 
keep track of what I was doing 
 
0 1 2 3 4 
My thinking has been slower than usual 0 1 2 3 4 
I have had to work harder than usual to 
express myself clearly 
 
0 1 2 3 4 
I have had to use written lists more often 
than usual so I would not forget things 
 
0 1 2 3 4 
I have trouble keeping track of what I am 
doing if I am interrupted 
 
0 1 2 3 4 
I have trouble shifting back and forth 
between different activities that require 
thinking 
 
0 1 2 3 4 
 
Comments From Others 
Never About 
once a 
week 
Two to 
times a 
week 
Nearly 
every 
day 
Several 
times a 
day 
Other people have told me I seemed to 
have trouble remembering information 
 
0 1 2 3 4 
Other people have told me I seemed to 
have trouble speaking clearly 
 
0 1 2 3 4 
Other people have told me I seemed to 
have trouble thinking clearly 
 
0 1 2 3 4 
Other people have told me I seemed 
confused 
0 1 2 3 4 
 
Perceived Cognitive Abilities 
Not at 
all 
A 
little 
bit 
Some-
what 
Quite a 
bit 
Very 
Much 
I have been able to concentrate 0 1 2 3 4 
I have been able to bring to mind words 
that I wanted to use while talking to 
someone 
 
0 1 2 3 4 
I have been able to remember things, like 
where I left my keys or wallet 
 
0 1 2 3 4 
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I have been able to remember to do things, 
like take medicine or buy something I 
needed 
 
0 1 2 3 4 
I am able to pay attention and keep track 
of what I am doing without extra effort 
 
0 1 2 3 4 
My mind is as sharp as it has always been 0 1 2 3 4 
My memory is as good as it has always 
been 
 
0 1 2 3 4 
I am able to shift back and forth between 
two activities that require thinking 
 
0 1 2 3 4 
I am able to keep track of what I am doing, 
even if I am interrupted 
0 1 2 3 4 
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Appendix E: Patient’s Assessment of Own Functioning Inventory (PAOFI) 
Instructions: Please answer each of the following questions by placing a check next to 
the response, which most accurately describes the way you have been recently. 
 
Memory: 
 
1. How often do you forget something that has been told to you within the last day or 
two? 
! Almost always 
! Very often 
! Fairly often 
! Once in a while 
! Very infrequently 
! Almost never 
 
2. How often do you forget events which have occurred in the last day or two? 
! Almost always 
! Very often 
! Fairly often 
! Once in a while 
! Very infrequently 
! Almost never 
 
3. How often do you forget people who you met in the last day or two? 
! Almost always 
! Very often 
! Fairly often 
! Once in a while 
! Very infrequently 
! Almost never 
 
4. How often do you forget things that you knew a year or more ago? 
! Almost always 
! Very often 
! Fairly often 
! Once in a while 
! Very infrequently 
! Almost never 
 
5. How often do you forget people whom you knew/met a year or two ago? 
! Almost always 
! Very often 
! Fairly often 
! Once in a while 
! Very infrequently 
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! Almost never 
 
6. How often do you lose track of time, or do things either earlier or later than they are 
usually done or supposed to be done? 
! Almost always 
! Very often 
! Fairly often 
! Once in a while 
! Very infrequently 
! Almost never 
 
7. How often do you fail to finish something you start because you forgot that you were 
doing it? (Include such things as forgetting to put out cigarettes, turn off stove, etc.) 
! Almost always 
! Very often 
! Fairly often 
! Once in a while 
! Very infrequently 
! Almost never 
 
8. How often do you fail to complete a task that you start because you have forgotten 
how to do one or more aspects of it? 
! Almost always 
! Very often 
! Fairly often 
! Once in a while 
! Very infrequently 
! Almost never 
 
9. How often do you lose things or have trouble remembering where they are? 
! Almost always 
! Very often 
! Fairly often 
! Once in a while 
! Very infrequently 
! Almost never 
 
10. How often do you forget things that you are supposed to do or have agreed to do 
(such as putting gas in the car, paying bills, taking care of errands, etc.)? 
! Almost always 
! Very often 
! Fairly often 
! Once in a while 
! Very infrequently 
! Almost never 
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Language and Communication: 
11. How often do you have difficulties understanding what is said to you? 
! Almost always 
! Very often 
! Fairly often 
! Once in a while 
! Very infrequently 
! Almost never 
 
12. How often do you have difficulties recognizing or identifying printed words? 
! Almost always 
! Very often 
! Fairly often 
! Once in a while 
! Very infrequently 
! Almost never 
 
13. How often do you have difficulty understanding reading material which at one time 
you could have understood? 
! Almost always 
! Very often 
! Fairly often 
! Once in a while 
! Very infrequently 
! Almost never 
 
14. Is it easier to have people show you things than it is to have them tell you about 
things? 
! Almost always 
! Very often 
! Fairly often 
! Once in a while 
! Very infrequently 
! Almost never 
 
15. When you speak, are your words indistinct or improperly pronounced? 
! Almost always 
! Very often 
! Fairly often 
! Once in a while 
! Very infrequently 
! Almost never 
 
16. How often do you have difficulty thinking of the names of things? 
! Almost always 
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! Very often 
! Fairly often 
! Once in a while 
! Very infrequently 
! Almost never 
 
17. How often do you have difficulty thinking of the words (other than names) for what 
you want to say? 
! Almost always 
! Very often 
! Fairly often 
! Once in a while 
! Very infrequently 
! Almost never 
 
18. When you write things, how often do you have difficulty forming the letters 
correctly? 
! Almost always 
! Very often 
! Fairly often 
! Once in a while 
! Very infrequently 
! Almost never 
 
19. Do you have difficulty spelling, or make more errors in spelling than you used to? 
! Almost always 
! Very often 
! Fairly often 
! Once in a while 
! Very infrequently 
! Almost never 
 
Sensorimotor: 
20. How often do you have difficulty performing tasks with your right hand (including 
such things as writing, dressing, carrying, lifting, sports, cooking, etc.)? 
! Almost always 
! Very often 
! Fairly often 
! Once in a while 
! Very infrequently 
! Almost never 
 
21. How often do you have difficulty performing tasks with your left hand? 
! Almost always 
! Very often 
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! Fairly often 
! Once in a while 
! Very infrequently 
! Almost never 
 
22. How often do you have difficulty feeling things with your right hand? 
! Almost always 
! Very often 
! Fairly often 
! Once in a while 
! Very infrequently 
! Almost never 
 
23. How often do you have difficulty feeling things with your left hand? 
! Almost always 
! Very often 
! Fairly often 
! Once in a while 
! Very infrequently 
! Almost never 
 
24. Lately do you have more difficulty than you used to in seeing all of what you are 
looking at, or all of what is in front of you (in other words, are some areas of your 
vision less clear or less distinct than others)? 
! Almost always 
! Very often 
! Fairly often 
! Once in a while 
! Very infrequently 
! Almost never 
 
Higher Level Cognitive and Intellectual Functions: 
25. How often do your thoughts seem confused or illogical? 
! Almost always 
! Very often 
! Fairly often 
! Once in a while 
! Very infrequently 
! Almost never 
 
26. How often do you become distracted from what you are doing or saying by 
insignificant things which at one time you would have been able to ignore? 
! Almost always 
! Very often 
! Fairly often 
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! Once in a while 
! Very infrequently 
! Almost never 
 
27. How often do you become confused about (or make a mistake about) where you are? 
! Almost always 
! Very often 
! Fairly often 
! Once in a while 
! Very infrequently 
! Almost never 
 
28. How often do you have difficulty finding your way about? 
! Almost always 
! Very often 
! Fairly often 
! Once in a while 
! Very infrequently 
! Almost never 
 
29. How often do you have more difficulty no than you used to in calculating or working 
with numbers (including managing finances, paying bills, etc.)? 
! Almost always 
! Very often 
! Fairly often 
! Once in a while 
! Very infrequently 
! Almost never 
 
30. Do you have more difficulty now than you used to in planning or organizing activities 
(i.e., deciding what to do and how it should be done)? 
! Almost always 
! Very often 
! Fairly often 
! Once in a while 
! Very infrequently 
! Almost never 
 
31. Do you have more difficulty now than you used to in solving problems that come up 
around the house, or at your job, etc.? (In other words, when something new has to be 
accomplished, or some new difficulty comes up, do you have more trouble figuring 
out what should be done and how to do it)? 
! Almost always 
! Very often 
! Fairly often 
! Once in a while 
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! Very infrequently 
! Almost never 
 
32. Do you have more difficulty than you used to in following directions to get 
somewhere? 
! Almost always 
! Very often 
! Fairly often 
! Once in a while 
! Very infrequently 
! Almost never 
 
33. Do you have difficulty than you used to in following instructions concerning how to 
do things? 
! Almost always 
! Very often 
! Fairly often 
! Once in a while 
! Very infrequently 
! Almost never 
 
 
 
  
